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A STUDY ON INCIDENCE OF MALIGNANCY IN PATIENTS 
UNDER GOING SURGERY FOR BENIGN THYROID DISEASES 
 
ABSTRACT: 
Keywords: Incidental thyroid carcinoma, Total thyroidectomy, Benign thyroid 
diseases. 
 
BACKGROUND: 
 Total thyroidectomy has been suggested by many people at various places for 
benign thyroid conditions which needs surgical intervention. According to them, one 
of the important factor  in substantiating total thyroidectomy is increased occurrence 
of incidental carcinoma in resected thyroid specimens. This study was conducted in 
our hospital to know the incidence of malignancy reported post operatively. 
METHOD: 
 This was a prospective observational study conducted in Coimbatore Medical 
College Hospital from the period of September 2011 to November 2012. This study 
included 109 consecutive patients operated for benign thyroid conditions in  our 
hospital. Patients having proven cytological diagnosis of malignancy were excluded 
from the study. Specimens of any form of thyroid surgeries( Hemithyroidectomy, 
subtotal thyroidectomy, Near total thyroidectomy, Isthumectomy) done for benign 
thyroid conditions were subjected to HPE by serial sectioning technique. HPE reports 
were documented and analysed. 
RESULTS: 
 Out of 109 patients (94 females and 15 males in the age range 16-88years), 7 
patients were found harbouring malignancy in the resected specimens(6.4%). There 
were 2 papillary micro carcinoma, 1 papillary carcinoma, 2  follicular carcinoma, 1 
minimally invasive follicular carcinoma and 1 lymphoma. Also it was observed that, 
there was no significant difference in the incidence of malignancy in MNG(6.5%) and 
SNG(5.4%) patients. 
CONCLUSION: 
 According to this study, the incidence of thyroid malignancy detected in 
patients operated for  benign conditions was 6.4%. Considering the morbidity 
associated with total thyroidectomy, it can be concluded that for benign thyroid 
conditions, conservative thyroid surgery followed by subjecting the specimens for 
thorough HPE examination and regular follow up of patients is sufficient, so that, 
positive cases of malignancy can be detected and treated accordingly.  
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                            INTRODUCTION 
      Goiter is defined as an enlargement of the thyroid gland. It may be 
diffuse or nodular. It may be toxic and non toxic. Further more, goiters 
are divided into endemic and sporadic depending on the prevalence of 
goiter in that area. World wide, nodular goiter remains an important 
health problem.   
    Benign thyroid swellings like nodular goiter and autoimmune 
thyroiditis are the most common thyroid diseases  in our country. 
Although they are benign, they may harbour malignancy that requires 
prompt and accurate diagnosis.  
   The thyroid malignancy remains the most common endocrine 
malignancy and have very good prognosis except few. Occult 
malignancies in thyroid swellings are increasingly reported nowadays 
worldwide due to improved diagnostic modalities. According to the 
literature incidental malignancies are more common in endemic areas. 
    In this part of Tamil Nadu, the soil has low iodine content and thyroid 
diseases are more prevalent. Hence this is conducted here to study 
incidence of  malignancies in patients operated for presumably benign 
thyroid diseases. 
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                       AIM OF THE STUDY 
 
Objectives of this study are: 
 
1. To find out the incidence of thyroid malignancy in patients 
undergoing surgeries for apparently benign thyroid diseases in 
CMCH. 
2. To study its distribution in age, sex, clinical presentation, and 
histological types. 
 
3. To find out the incidence of malignancy in patients with follicular 
neoplasm. 
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REVIEW OF LITERATURE 
                                          HISTORY [3,4] 
       The name „GOITER‟ was known since 2700 B.C, and was derived 
from the latin word „GUTTER‟, meaning throat. In the 7th century A.D, 
„Paul of Aegina‟ was the first physician who reported goiter. Initially he 
called it as bronchocele. In 1619 A.D, „Fabricus‟ identified the thyroid 
gland and identified that the goiters arise from it. The name „Thyroid 
gland‟ was derived from the greek word „thyreoeides‟ meaning shield 
shaped, it was meant to refer thyroid cartilage initially. The name thyroid 
was given by „Thomas Wharton‟ in 1656 A.D. 
Most people believed that goiters were caused by a toxin, a 
bacterium or a parasite in water. „Graves and Basedow‟ reported patients 
with goiter and palpitations. In 1820s the burnt seaweed containing iodine 
was found to treat goiters.  
Hypothyroidism was first defined in London in 1870s and was 
called „Myxedema‟. In 1895 „Baumann‟ found iodine in thyroid gland. In 
1914 „Kundal and Osterberg‟ isolated and named „thyroxin‟. In early 20th 
century it was found that small amount of iodine given to school girls in 
Akron, Ohio prevented goiters. 
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The first documented thyroid surgery for goiter was done by 
„Roger Frugardi‟ in 1170A.C, by seton suturing which had very high 
morbidity and mortality. With the advent of general anaesthesia, 
antiseptic techniques and hemostasis, in the latter half of  19
th
 century, 
thyroid surgery had its peak evolution in reducing morbidity and 
mortality.    
Emil Theodor Kocher(1841-1917), C.A. Theodar Billroth(1829-
1894), Charles Mayo(1866-1939),William Halsted(1852-1922) & George 
Crile(1864-1943) in the western world contributed a lot for thyroid 
surgeries. After that thyroid surgery had evolved little, till now. 
  Theodor Kocher was given Nobel prize in the field of medicine in 
1909 for his works on the thyroid gland. 
 
 
 
 
 
 
            
 
  Theodar  Kocher (1841-1917) 
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                           THYROID ANATOMY 
EMBRYOLOGY
[1,3,4]
: 
The thyroid gland develops from the midline diverticulum of 
primitive foregut. It arises from the foramen caecum at the tongue base. 
The midline diverticulum forms the medial thyroid anlage that is 
connected to foramen caecum through thyroglossal duct. Thyroid follicles 
arise from the cells of medial thyroid anlage. Lateral thyroid anlage arises 
from the fourth branchial pouch and fuses with medial thyroid anlage. 
The lateral anlage gives  rise to para follicular cells. They are 
neuroectodermal in origin. Thyroid gland development starts around third 
week of intrauterine life and colloid synthesis starts around eleventh week 
of gestation. 
 
 
 
 
 
 
  
 
                      Thyroid  Developement 
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THYROID GLAND
[1,3,4]
: 
   Thyroid is a highly vascular gland having two symmetrical lateral lobes 
united by an isthmus that is „H‟ or „U‟ shaped. It is situated in the anterior 
aspect of lower neck and its extent is from C5 to T1 level. It weighs 
around 25-30gms. It is covered by its own capsule and an envelope of 
pretracheal fascia. The lobes on either side extend from the oblique line 
of thyroid cartilage superioly, to 5
th
 or 6
th
 tracheal ring inferiorly. Isthmus 
lies infront of the  2
nd
, 3
rd
 and 4
th
 tracheal rings. 
  The lateral lobes are approximately triangular in cross section, 
having lateral, medial and posterior surfaces. The lateral surface lies deep 
to the strap muscles. The medial surface is related to lateral aspect of 
larynx, upper trachea, lower pharynx , upper esophagus, cricothyroid  and 
inferior constrictor muscles, recurrent and external laryngeal nerves. The 
posterior surface lies over the medial part of carotid sheath. The posterior 
surface of isthmus is firmly adherent to 2
nd
,3
rd
 and 4
th
 tracheal rings 
through pretracheal fascia.  
        The pretracheal fascia merges with the thyroid capsule posteriorly 
and laterally to form suspensory ligament of  Berry. It is attached to the 
cricoid cartilage and to the upper  tracheal rings which is responsible for 
up and down movement of  thyroid gland during swallowing along with 
the larynx. 
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RECURRENT LARYNGEAL NERVES
[1,3,4]
: 
     The right and left recurrent laryngeal nerves are branches of right and 
left vagus nerves respectively. The left recurrent laryngeal nerve recurves 
around the arch of aorta in the superior mediastinum and enters the 
tracheo esophageal groove and usually passes posterior to inferior thyroid 
artery, though variations may be present . The right nerve recurves 
around the right subclavian artery at the root of the neck and passes in the 
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tracheoesophageal groove. They provide motor supply to all pharyngeal 
muscles except cricothyroid and sensory supply to larynx and trachea.  
EXTERNAL LARYNGEAL NERVES
[1,3,4]
: 
    The external laryngeal nerve is also a branch of vagus nerve arising at 
the base of the skull, descends along internal carotid and lies closely 
behind the superior thyroid artery, runs on the surface of inferior 
constrictor muscle to supply cricothyroid. 
PYRAMIDAL LOBE
[1,3,4]
: 
     A pyramidal lobe may be present in around 50% of patients, 
projecting upwards from isthmus usually left to the midline. It develops 
from the distal end of thyroglossal duct. It may be attached to inferior 
border of  the hyoid bone through fibromuscular tissue named „levator 
glandulae thyroidae‟. 
THE PARATHYROIDS
[1,3,4]
: 
   The parathyroid glands usually lie behind the posterior surface of lateral 
lobes between thyroid and pretracheal fascia. They are usually four in 
number and each weighs around 40-50mgs.The superior gland is more 
constant in location, lies in middle of the back of the lobe at the level of 
first tracheal ring  above inferior thyroid artery. The inferior gland lies 
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usually within the pretracheal fascia behind the lower pole, buts its 
position may be highly variable. 
BLOOD SUPPLY
[1,3,4]
:  
  The thyroid gland receives its blood supply from superior and inferior 
thyroid arteries. Rarely in <3%  „thyroidae ima‟ artery a direct branch of 
aorta also produces little contribution. 
   Superior thyroid artery is the first branch of external carotid artery and 
it  pierces the pretracheal fascia as single vessel to reach upper pole of 
lateral lobe. The artery divides into anterior and posterior branches. The 
anterior branch runs down to isthmus to anastomose with its fellow artery 
from opposite side and the posterior branch descends on posterior surface 
to anastomose with inferior thyroid artery. 
  The inferior thyroid artery is a branch from thyrocervical trunk, that 
arches upwards and medially behind the carotid sheath and then passes 
downwards to the lower pole. It usually divides outside the pretracheal 
fascia into branches and pierce pretracheal fascia to reach the lower part 
of the gland. It supplies both superior and inferior parathyroid glands. 
During surgery it should be ligated well away from the gland, due to 
close proximity of recurrent laryngeal nerve to its branches. 
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  Venous drainage of the gland is through the superior , inferior and 
middle thyroid veins. Superior thyroid veins runs laterally along with 
superior thyroid arteries and drain into internal jugular vein directly. 
Middle thyroid veins also drains directly into internal jugular vein they 
are less consistent and sometimes may be multiple. During thyroid 
surgeries they should be ligated first. Both inferior thyroid veins  joins to 
form a plexus and drains into brachiocephalic veins. 
 LYMPHATIC DRAINAGE: 
   Thyroid gland has rich lymphatic supply. Lymphatic channels are 
present just beneath the thyroid capsule and they are highly 
intercommunicating. They drain mainly to deep cervical nodes, pre and 
para tracheal nodes, superior mediastinal nodes, nodes in relation to upper 
3
rd
 of esophagus. 
NERVE SUPPLY
[1,3,4]
:  
  Thyroid gland receives its sympathetic supply from superior, middle and 
inferior sympathetic ganglia. They reach the gland along with arteries. 
They are vasomotor to the gland. Parasympathetic supply is from the 
vagus nerve through its laryngeal branches. 
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HISTOLOGY
[1,2,3,4,7,8]
: 
  Thyroid gland is divided into multiple lobules through multiple septae 
entering into the gland from capsule. Each lobule has multiple follicles. 
Each follicle has a single layer of cuboidal cells surrounding a cavity 
containing thyroglobulin(colloid). Spaces in between follicles contain 
extensive capillary and lymphatic channels. They also contain connective 
tissues and parafollicular cells. During hyperfuntioning state, follicular 
cells become more columnar with decreased colloid substance. While in 
hypofunctioning state, follicular cells become more flat and follicles will 
contain abundant colloid substance. 
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           PHYSIOLOGY OF THE THYROID
[3,4,5,6] 
 Thyroid gland is an endocrine gland that secretes the hormone tri-
iodothyronine(T3), tetra-iodothyronine(T4) and reverse tri-
iodothyronine(rT3). T3&T4 are metabolically active, rT3is metabolically 
inactive. Thyroid hormones are synthesized in thyroid follicles.  
PITUITARY THYROID AXIS: 
   Thyroid stimulating hormone (TSH), secreted by anterior pituitary is 
the main regulating factor in thyroid hormone synthesis. Thyrotropin, a 
hormone secreted from the hypothalamus stimulates TSH synthesis and 
increased levels of circulating thyroid hormones (mainly T3) inhibits 
TSH secretion from anterior pituitary. Increased T3 has negative 
feedback effect both in hypothalamus and pituitary.  
   TSH acts on TSH-receptor (TSH-R) situated in the basolateral surface 
of thyroid follicular cells. It stimulates the follicular cells to increase the 
synthesis of  thyroglobulin and thyroid hormones. It also promotes 
growth and differentiation of follicular cells.  
IODINE METABOLISM IN THYROID: 
   Iodine is essential for thyroid hormones synthesis. Iodine is absorbed in 
the proximal small intestine in iodide form. Iodide is transported into the 
follicular cells against high concentration gradient via sodium-iodine 
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symporter situated in the basolateral surface of follicular cells. About 
90% of iodine in the body is in the thyroid gland. Iodide is oxidised to 
iodine and transported to exocytic vesicles to form iodotyrosyl residues 
and stored along with thyroglobulin as colloid in the cavity.  
SYNTHESIS AND TRANSPORT OF THYROID HORMONES: 
    Thyroglobulin(Tg) is a large glycoprotein, containing multiple tyrosine 
residues. Oxidised iodine bind to tyrosine residues in Tg to form 
monoiodotyrosine(MIT) and diiodotyrosine(DIT), catalysed by thyroid 
peroxidase enzyme situated in apical surface of the follicular cells. 
Coupling of  MIT & DIT gives rise to T3. Coupling of  DIT&DIT gives 
rise to T4. Both T3 and T4 are bound to Tg and stored in the colloid. 
When need arises Tg is taken back into the follicular cells by endocytosis. 
Proteolysis occurs in lysosomes to release thyroid hormones. They 
diffuse along the basolateral surface to enter the circulation. Rest of  the 
Tg is secreted again into the follicular cavity.  
   Thyroid gland produces predominantly T4 and less amount of T3. 
Majority of T3 is produced by peripheral deiodination of T4 that occurs 
in the liver, muscles, brain, kidneys. T3 is the most active thyroid 
hormone. >99% of thyroid hormones are protein bound, mainly 
thyroxine-binding globulin. Only free(unbound) thyroid hormones are 
active. The half life of T3is <1day whereas half life of T4 is around 7 
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days. Thyroid gland can store the reserve of thyroid hormones for 10-14 
days.  
THYROID HORMONE-FUNCTIONS: 
   Thyroid hormones are necessary to maintain normal metabolic 
activities. They are mandatory for fetal brain development  and skeletal 
maturation. They sensitise the heart to adrenaline, increase the BMR, 
regulates respiratory drive. They increase GI motility, plays vital role in 
carbohydrate, protein and fat metabolism. 
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                              EPIDEMIOLOGY 
   The most common thyroid disease in the community is simple 
goiter.The most common cause of thyroid diseases in the world is iodine 
deficiency that leads to goiter formation and hypothyroidism. In iodine 
sufficient areas, thyroid diseases are mainly caused by autoimmune 
diseases,that leads to hypo/hyperthyroidism.  
    A region is said to be endemic for goiter, if the prevelance of goiter is 
more than 10% among the children aged 6 to 12 years in that region. If 
the prevalence is less than 10% it is termed sporadic goiter.  
       In western countries the incidence of goiter has come down 
following measures like fortification of salt, fortification of fertilizers etc. 
Yet in certain parts of asia, Africa, Europe there is higher prevalence of 
goiter.  
       In India there is a goiter belt along the northern border extending 
from Jammu and Kashmir eastward along the southern valleys and 
foothills of Himalayas into Assam. Endemic goiter is also prevalent in 
Southern India. Coorg in Karnataka, north Arcot, foothills of Nilgris and 
Coimbatore are considered as endemic areas. 
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       Recent studies shows high frequency of thyroid disorders being 
detected in diabetes mellitus patients. High prevalence of hypothyroidism 
is seen in patients with Down‟s and Turner‟s syndrome. 
    Thyroid carcinoma contributes less than 2% of all malignancies and is 
also the most commonly seen endocrine malignancy(around 90%). 
Incidental carcinomas in thyroid are more common in endemic areas.  
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PATHOLOGICAL CLASSIFICATION OF 
THROID DISEASES
[7,8] 
1.THYROIDITIS 
A. Acute thyroiditis 
B. Granulomatous (De Quervain‟s) thyroiditis 
C. Other granulomatous inflammations 
D. Auto immune thyroiditis 
- Hashimoto‟s thyroiditis 
- Lymphocytic thyroiditis 
E. Reidel‟s thyroiditis 
2.HYPERPLASIA 
A. Dyshormonogenic goiter 
B. Grave‟s disease(Diffuse toxic goiter) 
C. Nodular hyperplasia 
3.TUMOURS 
A. Epithelial tumours 
- Follicular adenoma 
- Papillary carcinoma 
- Follicular carcinoma 
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- Hurthle cell tumours 
- Clear cell tumours 
- Squamous cell, mucinous and related tumours 
- Poorly differentiated carcinoma 
- Undifferentiated carcinoma 
B. Medullary carcinoma and related neuroendocrine tumours 
C. Lymphoid tumours and tumour like conditions 
D. Mesenchymal tumours 
E. Other primary tumours and tumour like conditions 
F. Metastatic tumours 
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       BENIGN DISEASES OF THYROID
[3,4,6,7,8]
          
ACUTE THYROIDITIS: 
Acute thyroiditis occurs due to infectious etiology of the thyroid, 
commonly following bacterial infection rarely fungi, parasites and virus 
may be the cause. Most common organisms isolated are streptococcus 
hemolyticus and staphyloccus aureus. Sometimes pneumococcus, gram 
negative bacteria, rarely candida, pneumocystis and cytomegalovirus may 
be the cause. Spread of infection occurs via haematogenous, by lymphatic 
route, penetrating injury to the neck and by pyriform sinus fistula. It 
occurs following URI, septicaemia, in immune compromised patients and 
debilitated individuals. Recurrent cases of acute suppurative thyroiditis 
occur mainly due to persistent pyriform sinus fistula. 
 
  
     
    
Patients usually present with neck pain radiating to jaw, fever, 
chills, odynophagia and dysphonia. Infections will cause neutrophilic 
infiltration and tissue necrosis, sometimes evolve into abscess. Diagnosis 
 
     A patient with acute 
thyroiditis turning into abscess 
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is made by FNAC. Treatment is usually medical, includes IV antibiotics, 
analgesics and symptomatic management. Thyroid abscess requires 
drainage, pyriform sinus fistula best treated by fistulectomy. 
GRANULOMATOUS THYROIDITIS: 
It is also known as De Quervains thyroiditis and sub acute 
thyroiditis. It usually occurs in middle aged women following upper 
respiratory tract viral infection. It has been suggested that the post viral 
inflammatory response is the cause for this condition. It is strongly 
associated with HLA B 35 haplotype. 
Patients usually present with sudden or gradual onset of neck pain 
radiating to mandible and ear. The gland is enlarged, firm and tender. In 
contrast to Riedel‟s thyroiditis there will not be adherence to adjacent 
structures.  Most of the patients initially have hyperthyroid phase, then 
hypothyroid phase and finally euthyroid phase. Microscopically, areas of 
inflammation with non-caseating granulomas, containing foreign body 
giant cells that characteristically surround the follicles are seen. ESR will 
be more than 100mm/hr. 
Medical treatment with NSAIDs and in severe cases steroids will 
be sufficient. Thyroidectomy is rarely indicated and is restricted to 
patients with recurrent disease and not responsive to medical treatment. 
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SUBACUTE PAINLESS THYROIDITIS: 
 It occurs between 30-60 years of age, either sporadically or in post 
partum period. It is thought to be an auto immune disease. Patients have 
normal or mildly enlarged, firm, non tender thyroid gland. Patients have 
normal ESR in contrast to painful thyroiditis. Patients are usually 
symptomatically managed with thyroxine or beta blocker. Thyroidectomy 
is rarely indicated, only in patients with recurrent and disabling episodes. 
OTHER GRANULOMATOUS INFLAMMATIONS: 
Palpation thyroiditis(Multifocal Granulomatous Folliculitis): 
 It is a common incidental finding noted during histopathological 
examination. It is thought to be caused by minor trauma to the gland or 
vigorous palpation on physical examination. It is clinically insignificant 
and grossly inconspicuous thyroid process. Microscopically, collections 
of histiocytes, lymphocytes and multinucleated giant cells are noted in the 
lumen of thyroid follicles. 
TUBERCULOSIS: 
 It rarely occurs as a primary clinical manifestation within the 
thyroid. It commonly occurs in disseminated miliary tuberculosis to form 
a tubercle within the gland. Sometimes, tuberculosis of cervical 
lymphnodes or larynx may involve thyroid gland secondarily. Patients 
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usually present with painless enlargement of thyroid. Diagnosis is 
confirmed by HPE. 
SARCOIDOSIS: 
 It can involve thyroid gland to form multiple interstitial non-
caseating granulomas. Usually it occurs in patients with systemic disease. 
Diagnosis is confirmed by HPE. 
MYCOSIS: 
 It is a very rare condition occurring in immuno-compromised 
patients with disseminated fungal infections. Most common organism 
causing this condition is Aspergillus. Histoplasma, Candida, Nocardia 
can also cause mycosis of thyroid. Microscopically, it is characterised by 
acute inflammation and necrosis and sometimes abscess formation. 
HASHIMOTO’S THYROIDITIS: 
 It is the common cause of hypothyroidism in non iodine deficient 
areas and the most common inflammatory disorder that affects thyroid 
gland. It commonly affects females (F:M-15:1), occurs in the 4
th
 and 5
th
 
decade. It was initially described by Hashimoto in 1912 as “STRUMA 
LYMPHOMATOSA” – transformation of thyroid tissue into lymphoid 
tissue. It is an auto-immune disease due to the production of antibodies 
against Thyroid Peroxidase(>90%), Thyroglobulin(60%), TSH-R(60%), 
23 
 
NaI symporter(20-25%). Follicular epithelial cell damage is mediated by 
both humoral and cell mediated immunity. It is also has been associated 
with increased intake of iodine and long term intake of drugs such as 
amiodarone, lithium and interferon alpha. It has been suggested that 
genetic predisposition also plays a role. 
 Clinically, the gland is diffusely enlarged, painless and firm. 
Sometimes patients may present with multinodularity, pressure 
symptoms, hypothyroidism and occasionally hyperthyroidism(<5%). 
Initially there may be hyperthyroid features but ultimately all the patients 
land up with hypothyroidism. 
Microscopically it is characterised by atrophied thyroid follicles, 
lymphocytic infiltration of the stroma and extensive oncocytic change of 
follicular cells. Fibrous variant of Hashimoto‟s thyroiditis is usually 
confused with carcinoma and Riedel‟s thyroiditis, characterised by very 
firm goiter, severe pressure symptoms and physical signs suggestive of 
cancer. Hashimoto‟s thyroiditis, along with lymphocytic infiltration of 
adrenal gland and other organ is known as „Schmidt‟s syndrome‟.    
Elevated TSH and the presence of antithyroid antibodies confirms 
the diagnosis. FNAC is done in patients with nodularity and rapidly 
enlarging goitre. Treatment includes Thyroxine in hypothyroid patients 
and in euthyroid patients to shrink the large goitre. Surgery may be 
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occasionally needed for patients with pressure symptoms, cosmetic 
deformity and suspicion of malignancy. 
Complications include high risk of developing Lymphoma(around 
80 fold) , Leukemia, Papillary Carcinoma, Hurthle cell neoplasms. 
LYMPHOCYTIC THYROIDITIS: 
Lymphocytic thyroiditis and Hashimoto‟s thyroiditis represent 
different phases of an organ specific autoimmune disorder, characterised 
by production of auto antibodies that affect thyroid function. 
Lymphocytic thyroiditis has been more commonly diagnosed in children. 
Diagnosis is made through FNAC. Usually patients present with 
asymptomatic goiter of short duration. Thyroid gland is diffusely 
enlarged, firm with vague nodularity. Microscopically, lymphocytic 
nodules with germinal centers are seen scattered in the interstitium. 
Clinical course mimics Hashimoto‟s thyroiditis. Surgery may be 
indicated in patients with pressure symptoms, rapidly enlarging goiter and 
suspicion of malignancy.  
REIDEL’S THYROIDITIS: 
It is an extremely rare form of thyroiditis that typically affects 
elderly females. It is also known as Invasive thyroiditis, Fibrous 
thyroiditis and Reidel Struma. Etiology is not clearly known. It is 
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associated with some auto immune diseases and may represent a 
manifestation of the group of idiopathic disorders known as 
„Inflammatory Fibrosclerosis‟ , that is associated with mediastinal, retro 
peritoneal and retro-orbital fibrosis and sclerosing cholangitis. 
 It may affect part or whole of a thyroid gland. When the whole 
gland is involved, patient may be hypothyroid. Patients usually presents 
with hard irregular, painless mass in the neck with respiratory difficulty, 
swallowing difficulty and voice change. Clinically, the mass will be very 
hard and fixed to the adjacent tissues. Diagnosis is confirmed by open 
biopsy that shows extensive fibrosis of the affected gland that extends 
beyond the capsule to the adjacent soft tissue. 
 Some patients may show response to corticosteroids and 
tamoxifene. Most patients need surgery to decompress trachea by wedge 
resection of the gland and to rule out the presence of malignancy. 
Complete thryoidectomy is very difficult to achieve due to the 
obliteration of tissue planes by fibrous infiltration. 
GRAVE’S DISEASE: 
 It was first described by Robert Grave in 1835. He initially 
described long and continuous palpitations in three young females and 
palpitations with eye signs in one young female. Grave‟s disease is 
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characterised by a triad of Diffusely enlarged thyroid gland, 
Hyperthyroidism and Ophthalmopathy. It is an autoimmune disease and 
has strong familial predilection. Female to male ratio is 5:1. Common age 
group is between 30-60years. Postpartum state, iodine excess, lithium 
therapy, bacterial and viral infections are suggested as possible 
stimulating factors for autoimmunity. Grave‟s disease may also be 
associated with autoimmune diseases like Type 1 DM, Myasthenia 
Gravis, Addison disease, Pernicious anemia.  
Autoimmunity cause production of Thyroid Stimulating 
Immunoglobulins(TSI) that binds to TSH receptor and produce long 
standing continuous stimulus to thyroid follicle cells causing increased 
rate of growth and excess synthesis of thyroid hormones. Clinically, 
patients will have heat intolerance, loss of weight inspite of good 
appetite, increased thirst and sweating, palpitations, diarrhoea, decreased 
sleep, tremors, amenorrhoea etc. Long standing cases may develop atrial 
fibrillation and high output cardiac failures. 
   Patients will have smooth, diffusely enlarged, non tender gland with 
increased blood supply evidenced by bruit, moist and warm skin. 
Widening of pulse pressure occurs due to cutaneous vasodilation. Fine 
tremors, proximal muscle weakness, muscle wasting and hyperactive 
tendon reflexes may also be present. Around 50% of patients with 
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Grave‟s disease will have eye signs including lid lag, widened palpebral 
fissure, proptosis, ophthalmoplegia etc.  Less than 2% of patients will 
have thyroid dermopathy.  
  Serum T3, T4 levels will be elevated, while TSH levels will be 
decreased. Elevated TSH-R Ab is diagnostic. 123 iodine uptake scan 
shows diffuse uniform uptake. Microscopically, the gland is hyperplastic 
containing tall columnar epithelial cells with scanty pale staining colloid 
and increased vascularity. Lymphocytic infiltration and aggregation may 
be present. Treatment includes antithyroid drugs, radioactive iodine 
ablation and thyroidectomy. Choice of treatment depends on several 
factors and individual preferences. 
DIFFUSE GOITER: 
  The enlargement of thyroid is called as goiter. It may be toxic or 
non toxic and can be endemic and sporadic. Diffuse goiter and MNG are 
most often caused by impaired thyroid hormone synthesis, due to iodine 
deficiency. The compensatory rise in TSH will cause hypertrophy and 
hyperplasia of follicular epithelial cells and enlargement of thyroid. 
Endemic goiter can also be caused by ingestion of goiterogens 
(excessive calcium, cabbage, cauliflower, cassava and turnips). Sporadic 
goiter occurs most commonly in females at the time of puberty or in 
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young life and goiterogens, hereditary enzyme deficiencies may be the 
cause. 
         Clinically the gland is diffusely enlarged, soft in consistency. 
Patients usually will be in euthyroid state. Microscopically follicles lined 
with hyperplastic, tall columnar epithelium - „Parenchymatous goiter‟. If 
iodine is available in adequate quantity or the demand of thyroid hormone 
synthesis decreases the follicular epithelium involutes and form colloid 
rich follicles-„colloid goiter‟. The cut surface of the gland appears glassy 
and translucent. The follicular epithelium is flattened and cuboidal with 
abundant colloid.  
NODULAR GOITER: 
Due to repeated episodes of hyperplasia and involution in untreated 
colloid goiter, irregular enlargement of gland occurs and is called as 
multinodular goiter. Usually MNG occurs in older individuals than 
colloid goiter. It occurs due to variations among follicular cells in 
response to various external stimuli. Both polyclonal and monoclonal 
nodules can coexist within the same MNG. Some longstanding MNG will 
develop into autonomous nodules that secrete thyroxine without TSH 
stimuli-„Toxic MNG‟. 
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Patients usually present with asymmetrically enlarged thyroid 
gland with pressure symptoms, often in euthyroid state. Sometimes they 
may grow behind the sternum – „Intrathoracic or Plunging goiter‟. 
Minority of patients may present with toxic symptoms. Sudden 
enlargement of the thyroid nodules happen sometimes due to 
haemorrhage. TFT will be normal. RAI scan shows patchy uptake with 
areas of hot and cold nodules. Incidence of malignancy in MNG is 5-
10%. Treatment involves suppression of TSH with thyroxine, 
thyroidectomy and radio iodine ablation. 
 
 
 
 
 
FOLLICULAR ADENOMA: 
Follicular adenomas of the thyroid are discrete, solitary masses 
resulting from clonal expansion of follicular cells due to gain of function 
(growth advantage) in TSH signalling system. For significant proportions 
of adenomas, etiology could not be identified. Clinically follicular 
adenomas are difficult to differentiate between other causes of nodular 
 
                        Diffuse goiter 
 
 
 
 
              Multinodular goiter 
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thyroid enlargement. Most of them present as unilateral, asymptomatic, 
solitary nodular swelling. Majority of them are non functional. Few 
adenomas may produce thyroid hormones independent of TSH 
stimulation and are termed as toxic adenomas – „Plummer‟s disease‟. 
Microscopically they have increased number of uniform appearing 
follicles, that contain colloid. The entire lesion is covered by well defined 
capsule with compression of adjacent thyroid tissue. FNAC cannot 
distinguish between follicular adenoma and carcinoma. Variants of 
follicular adenoma include colloid adenoma, atypical follicular adenoma, 
hurthle cell adenoma. Most of the adenomas take up less Radio active 
Iodine than normal thyroid parenchyma. About 10% of cold nodules 
eventually prove to be malignant on histologic analysis. Treatment 
includes thyroidectomy to rule out the presence of malignancy.    
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                       THYROID MALIGNANCIES[3,4,5,6,7,8] 
They account for less than 2% of all cancers. Most of the thyroid 
cancers occur in adults, but papillary carcinoma may occur at young age. 
Female sex is most frequently affected, particularly in early and middle 
adult age group. This may be related to neoplastic thyroid epithelium 
expressing oestrogen receptors. Carcinomas in childhood and late adult 
life have equal sex distribution. Even though most of the thyroid 
malignancies arise from thyroid follicular epithelium, each variant has 
different clinical and biological features.  
 There are various factors including genetic and environmental 
factors implicated in the pathogenesis of thyroid malignancies. Genetic 
factors play a main role in pathogenesis of Medullary thyroid 
cancer(MTC). Familial papillary and follicular carcinomas are very rare. 
Various gene mutations are involved in the histologic variants of thyroid 
malignancies. 
a. Follicular Carcinoma – Mutation in RAS family oncogenes and 
PAX 8-PPAR fusion gene. 
b. Papillary Carcinoma – Rearrangement of  RET or NTRK1, 
mutations in BRAF oncogenes, RAS mutation. 
c. Medullary Carcinoma – Mutations in RET protooncogene. 
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d. Anaplastic Carcinoma – Point mutation in p53. 
Ionising radiation is a major predisposing factor for developing 
thyroid cancer especially when exposure occurs younger than 20 years. 
Upto 9% of people exposed to radiation in head and neck will develop 
thyroid malignancies after many decades of exposure.  
Longstanding MNG has also been implicated as a risk factor in 
developing malignancy. Iodine deficient areas have higher prevalence of 
follicular carcinoma. Most of the thyroid lymphomas arise from the pre 
existing Hashimoto‟s thyroiditis. 
PAPILLARY CARCINOMA: 
 It accounts for 75-80% of all thyroid malignancies in iodine 
sufficient areas. It is the most common thyroid malignancy that occurs in 
adults with history of childhood radiation and in children. Female to male 
ratio is 2:1. Common age of presentation is 30-40 years. 
 
 
  
  
 
A case of Pap ca Anterior  view 
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 Most patients present with painless, enlarged hard mass in the 
thyroid region. They are usually euthyroid. Sometimes the initial 
presentation may be an enlarged neck node – “Lateral aberrant thyroid”. 
Dyspnoea, dysphagia and change in voice usually develop in locally 
infiltrative disease. Most common mode of spread is lymphatic spread. 
Hematogenous spread occurs in very few persons. Distant metastasis is 
seen in 20% of patients and common sites include lungs, bone, liver and 
brain. 
       FNAC is diagnostic. USG neck is mandatory to rule out the presence 
of neck nodes. On cut section, grossly the tumour may contain areas of 
calcification, necrosis and cystic change. Microscopically, the tumour 
may contain papillary projections. Cells are cuboidal and containing pale 
abundant cytoplasm with intranuclear grooves. The nuclei contain finely 
dispersed chromatin, which produces optically clear or empty 
appearance-„ORPHAN ANNIE EYED NUCLEI‟. 
  
 
   Cut section showing microcalcifications of 
papillary carcinoma 
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  Diagnosis of papillary cancer is mainly based on these nuclear 
features. Microscopic calcified deposits-„PSAMMOMA BODIES‟ may 
also be present. Multifocal lesions are identified upto 85% of specimens 
undergoing microscopic examination. 
              Variants of papillary carcinoma include encapsulated, tall cell, 
clear cell, follicular, insular, hyalinising trabecular and diffuse sclerosing 
type. They represent less than 1% of all papillary carcinoma and carry 
poor prognosis. 
 Patients with papillary carcinoma generally have excellent 
prognosis with ten year survival rate more than 95%. There are several 
scoring systems that include various factors as prognostic indicators. But 
the limitation is that the scoring system depends also on post operative 
HPE findings. Some of the scoring systems are 
a. AGES 
b. MACIS 
c. AMES 
d. Simplified system of De Groot and associates. 
e. TNM  
      Of these, the widely followed one is the TNM staging system. In 
general age greater than 40 years, extra thyroidal invasion, distant 
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metastasis, poorly differentiated tumour are associated with poor 
prognosis. Treatment of choice is total or near-total thyroidectomy with 
functional or modified neck dissection followed by radio active iodine 
ablation for ablating micrometastasis. 
PAPILLARY MICRO CARCINOMA: 
   They are defined as papillary carcinoma less than 1 cm in size with 
no capsular or blood vessel invasion and without lymphnode metastasis. 
Clinically they are undetectable. They are usually detected by HPE 
following thyroidectomy for benign conditions. Their incidence following 
surgery is varying from 4-14% in studies conducted in various parts of 
the world. Studies from autopsies have shown the incidence of occult 
papillary carcinoma ranging from 2-36%. 
 
 
 
 
 
 
 
 
  Papillary microcarcinoma, typical stellate scar like 
appearance. 
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         Generally occult papillary carcinoma is associated with very good 
prognosis. When occult papillary thyroid carcinoma diagnosed following 
lobectomy or isthumectomy for some benign conditions, completion 
thyroidectomy is not mandatory, unless the tumour has evidence of 
angioinvasion, multifocality, positive margins or high grade tumour. 
FOLLICULAR CARCINOMA: 
 Follicular carcinoma constitutes 10-15% of all thyroid 
malignancies. Their prevalence is more in iodine deficient areas than in 
iodine sufficient areas. Female to male ratio is 3:1. Mean age of 
presentation is around 50 years. They usually present as slow growing 
painless solitary nodule. Patients are generally euthyroid. Occasionally 
they may present in patients with longstanding goiter. Less than 1% of 
follicular carcinoma may present with features of thyrotoxicosis due to 
hyperfunctioning malignancies. Principal route of metastasis is 
haematogenous. Lymphatic metastasis is rare. 
  
 
 
 
 
 
Follicular Ca operated with 
skull metastases. 
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     FNAC cannot differentiate between follicular adenoma and follicular 
carcinoma. Pre operative clinical diagnosis of malignancy is suspected in 
patients with large lesions(greater than 4cms) in older men. DNA micro 
array test having being developed for differentiating benign and 
malignant follicular thyroid tumours. The specific micro RNAs, miR-197 
and miR-364 are upregulated in follicular carcinoma
[3]
. 
          Microscopically follicular carcinomas are single lesions and most 
of them are surrounded by a capsule. Malignancy is identified by the 
presence of capsular and vascular invasion, mainly involves large vessels. 
Tumour thrombus may be present in jugular and middle thyroid veins. 
Patients with FNAC diagnosis of follicular neoplasm should undergo 
lobectomy since atleast 80% of  patients have benign adenomas. 
Completion thyroidectomy should be performed in patients diagnosed as 
follicular carcinoma following lobectomy, so that radioactive ablation can 
be used to ablate metastasis.   
The cumulative mortality rate for follicular carcinoma is around 
15% in 10 years and 30% in 20years. Poor prognostic factors include age 
more than 50years, size more than 4cms, marked vascular and 
extrathyroidal invasion, high grade tumour and distant metastasis at the 
time of diagnosis. 
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MINIMALLY INVASIVE FOLLICULAR CARCINOMA: 
 Minimally invasive follicular carcinoma is less aggressive than 
widely invasive follicular carcinoma. It contains encapsulated lesions and 
have microscopic invasion through the capsule without extension into the 
normal glandular parenchyma . It may show invasion into small and 
medium sized vessels in the capsule or immediately outside the capsule, 
but not within the tumour. The role of completion thyroidectomy in 
minimally invasive follicular carcinoma is controversial. Larger the size, 
higher the grade. Older the age, one can proceed with completion 
thyroidectomy. 
HURTHLE CELL CARCINOMA: 
 Even though it is a variant of follicular carcinoma, it differs from 
follicular carcinoma in many ways. They are often multifocal and 
bilateral, more likely to metastasize through lymphatics to local nodes. 
They are less amenable to radioactive ablation. They account less than 
3% of all thyroid malignancies.  
 Hurthle cell carcinoma is also characterised by vascular and 
capsular invasion. Hence FNAC is not diagnostic. Microscopically, it is 
characterised by sheets of eosinophilic cells with abundant mitochondria 
that are devived from oxyphilic cells of thyroid gland. Lobectomy and 
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isthumectomy is adequate for hurthle cell adenoma. If it is confirmed as 
carcinoma by HPE, completion thyroidectomy along with central 
compartment node dissection is routinely performed. If needed MRND 
should be performed. Radioactive iodine ablation is not very effective in 
treating this tumour. 
MEDULLARY CARCINOMA THYROID: 
 It arises from the parafollicular  cells or „C‟ cells of the thyroid, 
that are concentrated in the superolateral portions of the thyroid lobes and 
secrete calcitonin. MTC accounts for 5-10% of all thyroid malignancies. 
Most of the MTC occurs sporadically. Around  25%  of  MTC occur as 
inhertited syndromes that include Familial Medullary Thyroid 
Carcinoma, MEN 2A and MEN 2B. Female to male ratio is 1.5:1. Most 
common age of presentation is 50-60 years. 
 Familial cases present in children and in younger age group. 
Patients usually present with enlarged neck mass with mild pain. There 
may be associated cervical lymphadenopathy. Locally invasive disease 
may produce dyspnoea, dysphagia and dysphonia. In addition to 
Calcitonin MTC secretes CEA, prostaglandins, serotonin and rarely 
ACTH. Patients with extensive metastatic disease may present with 
diarrhoea and electrolyte imbalance. 
40 
 
 MTC is usually unilateral in presentation in sporadic cases. In 
familial cases, it involves both lobes with features of multifocality. 
Microscopically, the tumour is composed of sheets of infiltrating 
neoplastic cells separated by collagen and amyloid. 
Immunohistochemistry for calcitonin is used as diagnostic tumour 
marker. All patients diagnosed as MTC should undergo screening for 
RET point mutations, pheochromocytoma and hyperparathyroidism.  
In patients with pheochromocytoma and MTC, pheochromocytoma 
should be operated first. Total thyroidectomy and bilateral central 
compartment neck dissection is the treatment of choice for tumours less 
than 1cm confined to thyroid and without cervical node involvement. 
Tumors greater than 1cm, palpable neck nodes should undergo MRND. 
Chemotherapy and radioactive iodine ablation are not effective. External 
beam radiotherapy is reserved for unresectable residual and recurrent 
tumours. Annual measurements of calcitonin and CEA are done for 
routine follow up. 
Stage is an important prognostic factor. Patients with tumour 
confined to thyroid will have 80% ten year survival rate whereas patients 
with node involvement has 45% ten year survival rate. Best prognosis is 
in patients with non-MEN familial MTC and worst prognosis is for MEN 
2B. 
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ANAPLASTIC  CARCINOMA: 
 This is an undifferentiated cancer arising from the thyroid 
epithelium. It is the most aggressive thyroid malignancy with 100% 
mortality within 6months to 1year of diagnosis. Females are most 
commonly affected. The common age group is 60-80 years. Patients 
usually present with rapid enlargement of a long standing goiter. It may 
be fixed to adjacent structures or overlying skin may be ulcerated. 
Compressive symptoms such as dyspnoea, dysphagia, hoarseness of voice 
are common. Both lymphatic and haematogenous metastasis can occur 
and they are usually present at the time of diagnosis. 
 It has been documented that around 50% of anaplastic carcinomas 
arise from the long standing MNG and 25% of patients with this tumour 
have a history of differentiated thyroid cancer(mostly papillary). 20-30% 
of patients have synchronous differentiated thyroid cancers.  
FNAC is diagnostic. Sometimes incision biopsy may be needed to 
confirm the diagnosis. Microscopically, sheets of cells with marked 
heterogeneity are seen. Cells may be giant and multi nucleated, spindle 
shaped, polygonal, small cells. There is no satisfactory treatment regime 
for patients with anaplastic cancer. Sometimes isthumectomy and 
tracheostomy may be needed to alleviate the airway obstruction. Younger 
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patients who are undergoing thyroidectomy for resectable mass may have 
improved survival. Adjuvant chemotherapy and combined radiation may 
also provide some survival advantage in these patients.  
LYMPHOMA:  
 Lymphomas constitute less than 1% of all thyroid malignancies. 
They usually arise from the patients with pre existing chronic 
lymphocytic thyroiditis and may arise as a part of generalised 
lymphomas. Patients usually have symptoms similar to anaplastic cancer, 
but the rapid enlargement of neck mass will not produce pain. Some 
patients may present with acute respiratory distress. Core needle biopsy 
or open biopsy is needed for the definitive diagnosis. Patients with extra 
thyroidal disease wil have poor prognosis.  
Thyroid lymphoma usually respond well to combined 
chemotherapy and radiotherapy. Cyclophosphamide, Adriamycin, 
Vincristine, Prednisolone is the commonly used regimen. Patients with 
respiratory obstruction who do not rapidly get relieved by chemo and 
radiotherapy needs surgical resection of the enlarged thyroid and  
lymphnodes to relieve the obstruction. The overall five year survival rate 
is around 50% . 
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SQUAMOUS CELL CARCINOMA: 
 Pure squamous cell carcinomas are exceptional in thyroid. 
Squamous cells may be found in thyroid as a result of persistent 
thyroglossal duct and structures derived from the pharyngeal pouch. 
Expression of squamous metaplasia may occur in Hashimoto‟s thyroiditis 
and papillary cancer. Tall cell variant of papillary carcinoma has a 
tendency to evolve into spindle cell type of squamous cell carcinoma. In 
the presence of pure squamous cell carcinoma, the possibility of 
secondary extension from the tumors of larynx, trachea or metastasis 
from other sites should be considered.  
METASTATIC TUMOURS: 
 Majority of metastatic tumours in thyroid are squamous cell 
carcinomas. In 10% of patients dying of malignant tumours, blood borne 
metastasis to thyroid is noted during autopsy. The most common site of 
primary tumour is skin(melanoma-31%), followed by breast, kidney,lung. 
Most commonly they are solitary lesions. Metastasis to thyroid is usually 
not misunderstood as primary thyroid tumour except in metastasis from 
renal cell carcinoma where it can present even decades after removal of 
primary tumour. Metastatic neuroendocrine tumour of various types can 
metastasize to thyroid gland and simulate MTC.  
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TERATOMA: 
    Teratomas of thyroid usually occur infants and children. Most of them 
are benign and cystic. They can cause obstruction of the airway. Thyroid 
teratomas in adult are very rare and are mostly malignant. 
OTHER MALIGNANCIES: 
 Plasmocytoma, Langerhan cell histiocytosis, Rosai-Dorfmann 
disease(sinus histiocytosis with massive lymphadenopathy) may involve 
thyroid as a part of systemic disease. Benign mesenchymal tumours like 
lipoma, hemangioma, lymphangioma, schwannoma, solitary fibrous 
tumour have also been reported. Sarcomas like fibrosarcoma, 
liposarcoma, leimyosarcoma, chondrosarcoma, osteosarcoma, peripheral 
nerve sheath tumour are also reported. 
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           EVALUATION OF THYROID GLAND 
THYROID FUNCTION TESTS
[3,4,5,6,]
: 
SERUM TSH:  
Measuring the level of serum TSH is the most important 
determinant of thyroid function. Normal TSH value is around 0.5-
5μU/ml. It is usually measured through immunometric assay.  Clinically 
euthyroid patient having normal TSH indicates a normally functioning 
thyroid gland. There is inverse relation between the levels of free T4 & 
TSH in serum.  A high TSH level indicates that the thyroid gland is 
hypofunctional, because of a problem that is directly affecting the thyroid 
(primary hypothyroidism). If the TSH level is low, it indicates that the 
person is having an overactive thyroid that is producing too much thyroid 
hormone (hyperthyroidism). Sometimes a low TSH may result from the 
reduced function of pituitary gland (secondary hypothyroidism). 
SERUM T4:  
     Thyroxine presents in blood in two forms,                                                           
1) protein bound form                                                                                           
2) free T4 – the biologically active form                                                                                                                             
It  can be measured as total T4 & free T4 by radioimmunoassay. Total T4 
levels indicate the output from thyroid gland. It is raised in hyperthyroid 
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conditions. It can also be raised in euthyroid patients with pregnancy, 
OCP use, hormone therapy, tamoxifen due to elevated levels of thyroid 
binding globulin (TBG). Similarly total T4 levels can be decreased, 
where TBG binding is reduced in conditions like nephrotic syndrome, 
androgen excess. Hence the measure of free T4 fraction is preferable than 
total T4, and tests to measure this are called the Free T4 (FT4) and the 
Free T4 Index (FT4I or FTI).  It can be measured directly through 
radioimmunoassay or indirectly through T3 resin uptake study. 
Individuals with hyperthyroidism will have an elevated FT4 or FTI, 
whereas patients who have hypothyroidism will have a low level of FT4 
or FTI. Combining the TSH test with the FT4 or FTI accurately 
determines the function of thyroid gland.  
The finding of an elevated TSH and low FT4 or FTI indicates 
primary hypothyroidism due to disease in the thyroid gland. A low TSH 
and low FT4 or FTI indicates hypothyroidism due to a problem involving 
the pituitary gland. A low TSH with an elevated FT4 or FTI is found in 
individuals with hyperthyroidism. 
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SERUM T3:  
      Serum T3 is also present in both, protein bound and  free form. They 
can be measured through radioimmunoassay. Serum T3 levels in normal 
thyroid conditions are more indicative of peripheral metabolism of 
thyroid hormone. Hence it is not suitable for general screening test. Free 
T3 tests are useful to diagnosis early hyperthyroidism or to determine the 
severity of the hyperthyroidism and to find out whether the patient is 
having T3 thyrotoxicosis. Patients who are hyperthyroid will have an 
elevated T3 level. T3 testing rarely is helpful in the hypothyroid patient, 
since it is the last test to become abnormal. Patients can be severely 
hypothyroid with a high TSH and low FT4 or FTI, but they have a normal 
T3 level. 
 
     HORMONES  NORMAL RANGE         UNITS 
 
           TSH 
 
         0.5 - 5.0 
 
       μU/ml 
 
             Total T4 
 
         55 – 150 
 
       nmol/L 
 
          Total T3 
 
         1.5 - 3.5 
 
       nmol/L 
 
              Free T4 
 
         12 – 28 
 
          pmol/L  
 
           Free T3 
 
           3 – 9 
 
          pmol/L 
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TRH EVALUATION:  
      This is used to evaluate TSH secretory function of anterior pituitary. 
TRH is administered intravenously(500μg) and TSH levels measured 
after 30 and 60 minutes. In a normal person, TSH level should be 
elevated at least 6μIU/ml from baseline. Failure to raise indicates 
pituitary cause of  hypothyroidism (secondary). 
THYROID ANTIBODIES: 
    Thyroid antibodies do not reveal thyroid function, but may indicate 
underlying etiology for thyroid dysfunction, usually autoimmune thyroid 
diseases. Thyroid antibodies include Anti-Tg, Anti- TPO and Thyroid 
stimulating immunoglobulin(TSI) . More than 95% of patients with 
autoimmune hypothyroidism and 80% of  patients with Grave‟s disease 
will have Anti-TPO at high levels. TSI stimulate TSH receptor in Grave‟s 
disease. Its main use is to predict neonatal thyrotoxicosis due to high 
maternal levels of serum TSI in last trimester of pregnancy. 
SERUM Tg LEVELS: 
    Serum Tg levels are increased in all types of thyrotoxicosis except 
Factitious thyrotoxicosis. Tg levels are increased in thyroiditis. The main 
use of measuring Tg is in the follow-up of thyroid cancer patients who 
underwent total thyroidectomy and radioablation. Tg levels should not be 
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detectable in follow-up and if there is measurable level of serum Tg, it 
indicates incomplete ablation or recurrence.  
SERUM CALCITONIN: 
   It is secreted by parafollicular or C cells of thyroid. Its normal level is     
0-4pg/mL. It is a sensitive marker for Medullary Carcinoma of 
thyroid(MTC). 
THYROID IMAGING
[3,4,5,6]
: 
RADIONUCLIDE SCANNING: 
    Radioisotopes I-123, I-125, I-131, 99mTc pertechnetate and 18-
fluorodeoxyglucose are used in radionuclide scanning of thyroid. These 
are selectively transported into the thyroid gland allowing imaging and 
quantifying the uptake.  
     
  
 
                Thyroid radioiodine uptake scan- 
123
I 
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       I-123 has half life of 12-13 hours and emits low dose radiation. 
Hence it is used to image the lingual thyroid and goitres. Whereas I-131 
has longer half life, around 8-10 days, and it is used to treat the patients 
having differentiated thyroid cancers with metastatic disease. 99mTc also 
having shorter half life, used for evaluation of thyroid gland. It is very 
sensitive in detecting nodal metastases. 18FDG-PET is more sensitive in 
detecting the metastases in thyroid carcinoma. It is particularly more 
effective in patients, in whom other types of radioimaging studies are 
negative.  
  In nuclear imaging, findings observed are as below, 
1. Grave‟s disease – increased, homogenous tracer uptake with 
enlarged gland 
2. Toxic adenoma – focal area of increased tracer uptake, with 
reduced   uptake in rest of the gland. 
3. Toxic MNG      - enlarged gland, with distorted architecture, with 
multiple areas of relatively increased or decreased tracer uptake. 
4. Sub acute thyroiditis – very low tracer uptake. 
5. Thyrotoxicosis factitia  – very low tracer uptake. 
     Thyroid radio nuclide imaging also used in follow-up of patients 
operated and radioablated for thyroid carcinoma. I-131 radioisotope is 
used for this purpose. 
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THYROID ULTRASOUND: 
   Ultrasound is a non invasive, easily accessible imaging modality. High-
resolution (7-15 MHz) ultrasound is the most sensitive imaging modality 
available for examination of the thyroid gland. It can diagnose nodules 
>1mm.  
         It is useful to detect whether a swelling arises from the thyroid or 
from the adjacent structures, calculate their dimensions, multicentricity, 
differentiate between solid and cystic component, identify the internal 
structure and vascularization , evaluate diffuse changes in the thyroid 
parenchyma and to check for presence of associated neck nodes. It is also 
used in guided FNAC.  
        There are certain sonographic findings that are more consistent with 
malignancy. They include presence of microcalcifications, irregular thick 
walled cystic cavity, hypo echogenicity, increased vasculature. Presence 
of  these findings are sonologic indications for FNAC. 
Role of CT , MRI, FDG-PET:  
  CT&MRI provide very good imaging of thyroid gland and nodal 
involvement, especially in very large goiters with retrosternal extension. 
Their relationship with airway and involvement of vascular structures can 
be well studied. For patients undergoing radio iodine ablation plain CT 
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should be taken, if contrast CT is taken therapy should be delayed for 
several months. 
  Combined PET-CT  has a limited role in diagnosis. It plays a vital role 
in  post-surgical management of a patient with thyroid cancer. It has been 
recommended for, 
1) patients with elevated serum thyroglobulin and negative 
radioiodine whole body scans  post operatively 
2) patients with adverse histology 
3) patients with high risk disease 
4) patients with histological diagnosis of  Hurthle cell carcinoma 
5) FDG-PET has also been advocated for post treatment response 
assessment. 
THYROID FNAC
[7,8]
: 
     Fine-needle aspiration cytology (FNAC) of the thyroid has become the 
best   test for preoperative evaluation of thyroid nodules. Thyroid  FNAC 
has reduced the number of unnecessary thyroid surgeries and has 
increased the proportion of cancers found before surgery.  
  According to the nature of the thyroid nodule, FNAC can function as a 
diagnostic test or a triage tool. As a diagnostic test, FNAC can be used to 
diagnose papillary carcinoma, poorly differentiated carcinoma, medullary 
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carcinoma , anaplastic carcinoma, metastatic malignancy, thyroiditis, and 
most benign nodular goitres and cysts. Yet follicular adenoma, well-
differentiated carcinoma and some hyper cellular goitres cannot be 
diagnosed through FNAC. 
Indications: 
-every patients with clinically palpable nodule should undergo FNAC. 
-incidentalomas that are detected by USG should undergo FNAC, if there 
is any presence of sonographic features that are suggestive of malignant 
nodule. 
-incidentalomas with PET scan avidity should undergo FNAC. 
-diffusely enlarged thyroid 
-unco-operative patients and patients with bleeding diathesis are 
contraindications for performing FNAC. 
Procedure: 
   Before doing a FNAC, a complete history should be obtained; a 
thorough physical examination of the thyroid gland and cervical lymph 
nodes should be performed; and a serum thyroid stimulating hormone 
level (TSH) and if possible thyroid ultrasound (US) should be obtained. 
  After antiseptic preparation of the neck, a 25 or 27 gauge needle 
introduced into the nodule without suction force, either through palpation 
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guided or ultrasound guided. Multiples passes in various directions made 
within the nodule, using single skin prick. If it is cystic cavity, containing 
fluid, a wide bore needle is introduced to aspirate the fluid content. Again 
the nodule size is reassessed and FNAC is performed. Contents are 
spilled into slides, air dried, stained and examined. Thyroid FNAC 
diagnostic criterias include, 
1) Nodular goiter/colloid nodule: plenty of colloid with an adequate 
number of benign follicular cells. 
2) Adenomatoid nodule: more cellular and less colloid than colloid 
nodule, no cytologic atypia present. 
3) Hashimoto‟s/Lymphocytic thyroiditis:in addition to the presence of 
benign follicular cells, abundant reactive lymphoid cells are present in the 
background. 
4) Suspicious for malignancy: Nuclear features and cellular 
arrangements are suggestive of a speciﬁc type of malignant tumor; 
however, a deﬁnite diagnosis cannot be made out due to inadequate 
cellularity. 
5) Malignant: Cellular features are diagnostic of a speciﬁc thyroid 
cancer, lymphoma, sarcoma, etc. 
6) Atypical: Nuclear atypia such as nuclear enlargement, nuclear 
grooves, nuclear pseudo-inclusions, and prominent nucleoli are present 
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focally in a few clusters of follicular cells, but the rest of the smear is 
otherwise consistent with nodular goiter or thyroiditis. 
 Atypical lymphoid cells present in a background of Hashimoto‟s 
thyroiditis, which cannot be distinguished between lymphoma and 
reactive lymphoid hyperplasia. 
7) Follicular neoplasm: Cellular specimens with scant or absent 
colloid, consisting of many syncytial sheets or microfollicles with 
enlarged nuclei, coarse chromatin, and prominent nucleoli. 
8) Follicular lesion:  Cytologic smears from different passes of the 
FNAC show a spectrum of cytologic features, ranging from a benign 
nodular  goiter to a possible follicular neoplasm. 
 
9) Inadequate:  Insufﬁcient number of follicular cells (8–10 clusters 
on two slides) in specimens with scant or absent colloid. 
The Bethesda System for Reporting Thyroid Cytopathology: 
     For clarity of communication, the Bethesda System for Reporting 
Thyroid Cytopathology recommends that each report begin with a general 
diagnostic category. Each of the categories has an implied cancer risk  
that links it to a rational clinical management guideline. Recommended 
Diagnostic Categories include, I- non diagnostic, II- b benign, III- 
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atypia/follicular lesion of undetermined significance, IV- follicular 
neoplasm, V- suspicious for malignancy, VI- malignancy. 
Implied Risk of Malignancy and Recommended Clinical 
Management 
      Category Risk of malignancy % Usual management 
              I              1-4 Rpt FNAC with USG guidance 
              II              0-3 Clinical follow up 
              III              5-15 Repeat FNAC 
              IV              15-30  Lobectomy 
              V              60-75 Near total thyroidectomy or lobectomy 
              VI              97-99 Near total thyroidectomy 
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                           TREATMENT OPTIONS 
MEDICAL THERAPY
[3,4,5,6]
: 
     Antithyroid drugs such as Propylthiouracil, methimazole, carbimazole 
acts by binding to thyroid peroxidase and thereby inhibit the iodination of 
tyrosine residues in thyroglobulin and coupling of iodotyrosine  residues 
In addition propylthiouracil also inhibits peripheral conversion of T4 to 
T3. They are used in the treatment of hyperthyroidism that occurs in 
Graves disease, toxic MNG and thyroid storm. Propanolol is the drug 
used for controlling sympathetic symptoms in hyperthyroidism. 
     Thyroxine tablet of 100-150 μgs used for hypothyroidism. They are 
also used to shrink the goiter size and in block and replacement therapy. 
RADIOACTIVE IODINE ABLATION THERAPHY
[3,4,5,6]
: 
 Affinity of the hyperplastic thyroid gland to iodine forms the basis 
of RAI ablation. I-131 is most commonly used, administered orally. 
Usual therapeutic dose is 8 to 12 mc. When taken up by the gland, RAI 
disintegrates within the gland and emits beta particles which destroy the 
acinar cells. Since beta particles penetrate only few millimeters, 
surrounding normal tissues are not affected. 
 Before ablation a preliminary isotope scan is done to assess the size 
of the gland. All patients should be made euthyroid before treatment. 
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Also antithyroid drugs should be stopped 2-3 weeks before therapy to 
facilitate iodine uptake by the gland. Response to therapy is usually slow 
takes 8-12 weeks. 
Indications: 
1. Older patients with small or medium sized goiter. 
2. When surgery or antithyroid drugs are contraindicated. 
3. Following relapse after surgery or medical treatment. 
Absolute contraindications: Pregnancy and Lactation. 
Relative contraindications: Ophthalmopathy, young patients and 
presence of thyroid nodules. 
Complications: 
                IMMEDIATE                          LATE 
1. Neck pain, swelling, tenderness 
2. Nausea and vomiting 
3. Thyroiditis 
4. Sialadenitis 
1. Bone marrow suppression 
2. Increased incidence of 
Leukaemia, thyroid and other 
malignancies 
3. Chronic sialadenitis, nodules 
4. Worsening of ophthalmopathy 
5. Hypothyroidism and 
hypoparathyroidism 
6. Infertility and abortion 
 
59 
 
    
SURGICAL MANAGEMENT
[3,4,5,6,32]
: 
Pre-operative planning: 
 As with any surgery, a detailed discussion with the patient is to be 
made about the indications, alternate treatment options and possible 
complications following thyroidectomy. Complications include injury to 
recurrent laryngeal nerve, resulting in hoarse voice, post-operative 
hypoparathyroidism leading to transient hypocalcaemia(10-20%) and 
even permanent hypocalcaemia(1-2%), injury to cervical sympathetic 
trunk(in invasive thyroid cancers and retro esophageal goiters) resulting 
in Horner‟s syndrome and very rarely bilateral vocal cord dysfunction 
with airway compromise requiring tracheostomy. Patients should be 
aware that after subtotal and total thyroidectomy, they will be required to 
take lifelong thyroid hormone replacement. After the detailed discussion, 
informed consent for surgery is obtained. 
Pre-operative evaluation: 
 Apart from basic investigations for anaesthetic fitness, all patients 
should be evaluated with thyroid function test, serum calcium and 
parathormone level. Further patients with any recent or even remote 
history of hoarseness of voice and those with history of previous neck 
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surgery should undergo vocal cord assessment with direct or indirect 
laryngoscopy. 
Pre-operative management: 
 It is essential that a patient is in euthyroid state prior to surgery to 
avoid the risk of developing a thyroid storm during surgery. This is 
usually achieved in 6 weeks using antithyroid drugs like propylthiouracil 
100 to 300 mg thrice daily or methimazole 10-30 mg thrice daily. 
Propranolol 40 to 120 mg thrice or four times a day is used to control 
symptoms like tachycardia, anxiety, tremors and heat tolerance. 
Potassium iodide1 drop or Lugol‟s iodine solution 5 to 10 drops twice or 
thrice a day is given for 14 days before surgery to decrease the 
vascularity of the gland and thereby facilitating surgery. 
Surgical technique: 
 General anaesthesia is always preferred. Patient is positioned 
supine, with a sandbag between the scapulae, neck well extended and 
head placed on a head ring. Hyperextension is to be avoided. Correct 
positioning ensures that the isthmus of thyroid lies over second and third 
tracheal rings just caudal to the cricoids cartilage and will allow good 
exposure and access to the surgeon. 
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HEMITHYROIDECTOMY: 
        The skin incision is placed 1 cm below the cricoid cartilage, along 
the Langer‟s lines. The incision should be centrally placed and should be 
neither too low nor too high. The incision is deepened up to the platysma, 
where an avascular plane is reached. Blunt dissection is performed in this 
plane superiorly and inferiorly and flaps raised. 
 
 
 
 
 
 
 
 
 
 
 
 
Positioning and marking the incision 
 
   Flaps raised & deep fascia opened 
 
         Ligating the syperior pedicle 
 
        Hemithyroidectomy specimen 
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         The strap muscles are separated using electro cautery after dividing 
the cervical fascia in the midline. Ipsilateral strap muscles are retracted 
and blunt dissection performed between them and the gland. Once the 
thyroid lobe is exposed, superior pole vessels are mobilized and ligated 
close to the gland to avoid injury to superior laryngeal nerve. After 
mobilization of upper pole, remaining lobe is retracted antero-medially 
and blunt dissected laterally. The middle thyroid vein is ligated and 
divided and the lobe is delivered out of the wound. Recurrent laryngeal 
nerve and parathyroid glands are identified. The inferior thyroid vessels 
are identified and ligated away from the gland to avoid damage to the 
recurrent laryngeal nerves. Care should be taken to divide only the 
terminal branches entering the gland as inferior pole vessels also supply 
the inferior parathyroids. 
           The final dissection off the anterolateral aspect of the trachea 
through the ligament of Berry is performed and thyroid isthmus is 
mobilized up to the intersection with contralateral lobe, and then divided. 
Specimen is re-examined to ensure no parathyroid is inadvertently 
removed. Strap muscles are reapproximated followed by rest of the 
wound. 
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SUBTOTAL THYROIDECTOMY: 
          The recommended resection for subtotal thyroidectomy involves 
removal of total lobectomy and isthumectomy on the most diseased side 
and a subtotal resection leaving 4g of tissue on the contralateral side.  
         A thyroid lobectomy is performed on the diseased side as described 
before. On the side of subtotal resection, the upper pole vessels and 
middle thyroid vein are divided. However the branches of inferior thyroid 
artery are not ligated and a postero-lateral resection margin through the 
thyroid is made, along which it is transected.  Keeping the posterior 
thyroid capsule intact helps to protect the nearby recurrent laryngeal 
nerve and parathyroid glands.  
NEAR-TOTAL THYROIDECTOMY: 
       Near-total thyroidectomy leaves less than 1 g (1 cm) of thyroid tissue 
on side of neck. It is performed when total thyroidectomy is planned but 
deemed unsafe to do in order to preserve recurrent laryngeal nerve or 
parathyroid gland. 
Complications of surgery: 
 Haemorrhage: A tension hematoma deep to cervical fascia may 
develop, due to slipping of ligature on superior thyroid artery. 
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 Respiratory obstruction: Due to laryngeal oedema or 
collapse/kinking of trachea and/or tension hematoma. 
 Recurrent laryngeal nerve paralysis: Can be unilateral or bilateral, 
transient or permanent.  
 Thyroid insufficiency: Usually seen within 2 years after surgery. 
 Parathyroid insufficiency: This is due to inadvertent removal or 
infarction of parathyroids due to damage to parathyroid end artery. Most 
cases present 2-5 days after surgery. 
 Wound infection 
 Hypertrophic or keloid scar. 
 Stitch granuloma.  
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                       MATERIALS AND METHODS 
Study design : Prospective-observational study 
Study period: September 2011-november 2012 
Study place: Coimbatore government  medical college hospital 
,Coimbatore 
Study population: A total number of 109 consecutive patients, who 
underwent some form of thyroid surgeries in all surgical units of our 
hospital. All these patients had clinically, radiologically and cytologically 
proven benign thyroid conditions. Patients with cytological report of 
follicular lesion were also included in the study. 
Exclusion criteria: 
1. Patients with age less than 12 years. 
2. Patients having clinical, radiological and cytological evidence of 
malignancy. 
3. Patients with enlarged cervical nodes with proven secondary 
deposits. 
4.  Patients with recurrent thyroid swelling. 
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 For all patients written informed consent was obtained. Thorough history 
taking and clinical examination was done as per previously formed 
proforma case sheet. 
  History regarding residence, dietary intake, drug intake, duration of 
swelling and recent increase in size, symptoms of hyper/hypothyroidism, 
pressure symptoms, symptoms of metastases, radiation exposure, 
involvement in other family members were sought. 
  Physical examination to find out nodularity, fixity, presence of neck 
nodes, lung and skeletal metastases was done. 
  Each patient was subjected to ENT examination to document vocal 
mobility. 
  X –ray neck and chest were taken to look for tracheal compression, and 
to look for lung metastases. 
   Serum TSH, total T4, total T3 were estimated in all of the patients. For 
patients with normal TSH and abnormal total hormones free T3 and free 
T4 also estimated.   
   Each patient has undergone USG neck to look for clinically 
undetectable nodules, to look for suspicious lesions and neck nodes. 
   FNAC was done for each patient in the Department of pathology. For 
patients with multinodular goitre FNAC was perfomed in all dominant 
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nodules and non dominant nodules of  >1cm size and radiologically 
suspicious nodules. 
  Two patients with retrosternal extension of goitre were subjected to  CT 
thorax. 
   Radioisotope scan was not done, as that facility is not available in our 
hospital. 
     Baseline investigations include blood sugar, blood urea, serum 
creatinine, complete hemogram, blood grouping, VCTC , serum HbsAg, 
ECG taken for all patients. For patients >50 years and patients with 
features of hyperthyroidism, cardiologist opinion obtained regarding 
fitness for surgery. 
    All patients were admitted. Co existing problems, if present were 
corrected or controlled ( toxic symptoms,  anaemia, diabetes, 
hypertension) and prepared for surgery. 
   The criterias for selection of surgery include pressure symptoms, 
cosmesis, toxicity, suspicious of malignancy and individual preferences.  
  Per-operative findings for all patients were recorded. Specimen sent for 
HPE and histopathology reports were recorded. All patients were 
followed  till discharge.    
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                        OBSERVATIONS 
AGE AND SEX DISTRIBUTION FOR PATIENTS PRESENTED 
WITH BENIGN THYROID DISEASES:    
     Of total 109 patients presented with benign thyroid diseases 94 
patients were female and 15 patients were male. Most common age group 
of presentation for  female is  20-40 years. The most common age group 
of presentation for male is  30-40 years.   
 
 
 
 
 
 
 
 
 
 
 Male to female ratio for patients underwent surgery for benign thyroid 
diseases is  1:6.3 
 
        AGE         MALE    FEMALE    TOTAL 
13-20 years 1 3 4 
21-30 years 2 32 34 
31-40years 6 28 34 
41-50 years - 17 17 
51-60 years 4 10 14 
>60 years 2 4 6 
TOTAL 15 94 109 
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    There is a rising trend after 20 years of age and falling trend following 
40 years of age. Mean age for presentation of benign thyroid diseases is 
38.4 years. Range of the age distribution is 17-88 years.  
 
  
15 
94 
Male to Female ratio 
Male
Female
1 2 
6 
0 
4 
2 
3 
32 28 
17 
10 
4 
0
5
10
15
20
25
30
35
40
13-20 years 21-30 years 31-40 years 41-50 years 51-60 years  >60 years
Female
Male
70 
 
CLINICAL PRESENTATION: 
    Of all cases there were 55 patients (46 females and 9 males) presented 
with SNG, 48 patients(46 females and 2 males)  with MNG and 8 patients 
(4 females and 4 males) with diffuse goiter. For MNG female to male 
ratio is 22:1, for SNG it is around 5:1 and for diffuse goiter it is 1:1 
 
 
  Of 8 patients with diffuse goiter ultrasound detected multinodularity in 2 
patients. And 5 of them were having hyperthyroid hormonal profile. And 
4 of them had FNAC finding of  nodular goiter with toxic changes.  
Majority of patients with SNG having right side involvement (35 of 55 
patients). 18 patients had left side swelling and 2 patients had isthmus 
nodule. The right to left ratio was around 2:1.  
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PRE-OP CYTOLOGICAL DIAGNOSIS OF BENIGN THYROID 
DISEASES:  
 
    The most common cytological diagnosis found was nodular goiter, 
around 56%. Of 109 patients 12 patients had uncertain diagnosis of 
follicular neoplasm/nodular goiter and 13 patients had follicular 
neoplasm. 9 patients had colloid goiter, 6 patients had adenomatous 
goiter, 4 patients toxic goiter and 4 patients had Hashimoto‟s thyroiditis. 
 
 
 
 
61 
13 
12 
9 
6 
4 4 
Pre op Cytological diagnosis 
NG
FN
FN/NG
CG
AG
MNG-Toxic
HT
72 
 
 THYROID SURGERIES PERFORMED FOR BENIGN THYROID 
DISEASES: 
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      Hemithyroidectomy was the most commonly performed procedure, 
around 50%. Hemithyroidectomy most commonly performed for solitary 
nodular disease, in some patients  hemithyroidectomy was done for 
multinodular disease occupying single lobe. Of 3 isthumectomies, 2 were 
done for nodular goiter in isthumus and 1 was done in emergency setup in 
patient with respiratory obstruction along with tracheostomy. This patient 
had cytological diagnosis of  Hashimoto‟s thyroiditis. 
INCIDENCE OF MALIGNANCY: 
    Incidence of malignancy in patients undergoing surgery for benign 
thyroid diseases found was 6.4%. Total number of malignancies detected 
by post operative histopathological examination were 7 out of 109 cases.  
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HISTOLOGICAL VARIANTS OF MALIGNANCIES: 
      Of total 7 malignacies, 6 were well differentiated malignancies  
including      3 papillary carcinomas and 3 follicular carcinomas that arose 
from thyroid follicular epithelium and 1 was low grade lymphoma. 
 
 
CASES AGE/SEX FNAC DIAGNOSIS PROCEDURE HPE 
Case 1 30/F NG SNG  Rt Rt 
hemithyroidectomy 
Follicular 
carcinoma 
Case 2 34/M NG SNG Rt Rt 
hemithyroidectomy 
Papillary 
carcinoma 
Case 3 30/F FN SNG Rt Rt 
hemithyroidectomy 
Follicular 
carcinoma 
Case 4  46/F HT MNG N/T thyroidectomy Microscopic 
papillary Ca 
Case 5 58/F NG MNG N/T thyroidectomy Microscopic 
papillary Ca 
Case 6 55/M HT DG Isthumectomy Low grade 
Lymphoma 
Case 7 40/F FN MNG S/T thyroidectomy Follicular 
carcinoma 
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  Of 3 papillary carcinomas 2 were microscopic papillary carcinoma in 
non dominant nodules of around 4mm and 6mm in largest diameter, they 
existed amidst their original pathology( MNG & Hashimoto‟s 
thyroiditis). No multifocality noted. 1 patient was diasnosed as papillary 
carcinoma following hemithyroidectomy, he underwent completion 
thyroidectomy 2 months later. Completion thyroidectomy specimen was 
also harbouring tumor. 
   Of 3 follicular carcinomas one was minimally invasive follicular 
carcinoma, not completely penetrating the capsule and one was low grade 
follicular carcinoma. Third one was the invasive follicular carcinoma 
with vascular and capsule invasion. 
  One case of low grade lymphoma was diagnosed following 
isthumectomy in emergency setup. 
 
 
 
  
 
  
 
76 
 
 
AGE DISTRIBUTION OF INCIDENTAL MALIGNANCIES: 
    There were 4 cases of incidental malignancies between 21-40 years age 
group and 3 cases of incidental malignancies between 41-60 years age 
group. The mean age for presentation of incidental malignancy is 41.9 
years. 
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INCIDENTAL MALIGNANCY – SEX & CLINICAL 
PRESENTATIONS: 
 Incidental malignancy was diagnosed  2 out of 15 male patients, 13.3%  
of all male cases. And in female patients 5 cases of malignancy diagnosed 
out of 94 patients,5.3% of all female cases. 
GOITER SEX BENIGN MALIGNANT TOTAL 
 
SNG 
Male 8 1 9 
Female 44 2 46 
 
MNG 
Male 2 - 2 
Female 41 3 44 
 
DIFFUSE 
GOITER 
Male 3 1 4 
Female 4 - 4 
TOTAL  102 7 109 
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NATURE OF THYROID ENLARGEMENT: 
   3 cases of incidental malignancies were diagnosed in 55 cases of SNG. 
Incidence in SNG is 5.4%. 
  3 cases of incidental malignancies were diagnosed in 46 cases of SNG. 
Incidence in MNG is 6.5%.  
  One case of incidental malignancy was diagnosed in 8 cases of diffuse 
goiter. Incidence in diffuse goiter is 12.5%. 
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CYTOLOGICAL CORRELATION WITH INCIDENTAL 
MALIGNANCIES: 
   Malignancy detected in 3 patients out of 61 patients with cytological 
diagnosis of  nodular goiter (including MNG). Incidence of  malignancy 
in nodular goiter was 4.9%. 
  Malignancy detected in 2 patients out of 25 patients with follicular 
neoplasm & follicular neoplasm/nodular goiter. Incidence of malignancy 
in FN & FN/NG was 8.0%. 
  Malignancy detected in 2 patients  out of 4 patients with Hashimoto‟s 
thyroiditis. Incidence of malignancy in Hashimoto‟s thyroiditis was 
50.0%. 
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SURGICAL PROCEDURES AND MALIGNACIES 
    Out of 55 hemithyroidectomies 3 cases reported as malignancy. They 
were 2 follicular carcinomas and 1 papillary carcinoma. Completion 
thyroidectomy  for all three cases were performed. For patients operated 
for follicular carcinoma there was no evidence of malignancy. For patient 
operated for papillary carcinoma residual thyroid tissue also had evidence 
of malignancy. 
   We have done subtotal thyroidectomy for 41 patients, of them one 
patient had microscopic papillary carcinoma which was in the same lobe 
of nodular goiter. Another patient had follicular carcinoma limited to 
thyroid. 
  We have performed 10 near total thyroidectomies of them one had 
microscopic papillary carcinoma which was a single lesion in the 
background of  Hashimoto‟s thyroiditis. 
   Three patients underwent isthumectomy. Two were done under elective 
setting of solitary nodular colloid goiter in isthmus. One was performed 
under emergency setting along with tracheostomy to relieve respiratory 
obstruction who had FNAC report of Hashimoto‟s thyroiditis. That 
patient‟s HPE report was Low grade Lymphoma.  
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DISTRIBUTION ACCORDING TO SURGICAL PROCEDURES: 
 
 
  We have performed surgery for 4 patients with Hashimoto‟s thyroiditis. 
Three of them presented like MNG with pressure symptoms. Of them one 
patient had microscopic papillary carcinoma in the background of 
Hashimoto‟s thyroiditis. One patient with cytological diagnosis of 
Hashimoto‟s underwent isthumectomy and HPE proved to be low grade 
lymphoma. 
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OVERALL HPE REPORTS FOLLOWING SURGERY FOR 
BENIGN THYROID DISEASES : 
                  DISEASES  NO.OF.CASES 
Multinodular goiter 34 
Follicular adenoma 31 
Adenomatous goiter 27 
Hashimoto‟s thyroiditis   4 
Papillary carcinoma   3 
Follicular carcinoma   3 
Toxic goiter   2 
Lymphoma    1 
Colloid goiter   1 
Hurthle cell adenoma   1 
TB thyroid   1 
MNG toxic   1 
TOTAL 109 
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                                  DISCUSSION 
  Totally 109 cases of benign thyroid diseases were operated in our 
hospital in the study period. In 109 cases 94 were female and 15 were 
male with female to male ratio is 6.3:1consistent with the study of Foad 
Ali Moosa
[9]
et al. Overall mean age of presentation was 38.4 years and 
the range was16-88 years. 
  The most common clinical presentation was SNG- 50.5%, followed by 
MNG-42.2%. Diffuse goiter constituted around 7.3%.. For patients with 
SNG mean age of presentation was35.7years. For patients with MNG 
mean age of presentation was 39.5 years.  
  The most common benign cytological diagnosis was nodular goiter 
presented in 56% of cases. For its indeterminate nature, cytology reported 
as follicular neoplasm and follicular neoplasm/nodular goiter are 
considered as a single entity and compromised around 23% of all benign 
cases. Remaining was contributed by colloid goiter, adenomatous goiter , 
MNG toxic goiter and Hashimoto‟s thyroiditis in order of decreasing 
frequency. 
  HPE reports of  the patients treated surgically for benign thyroid 
diseases were recorded and the results were analysed. The findings were 
expressed as absolute numbers and as percentages. 
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  Incidence of malignancy in this series was 7 cases in 109 cases, that 
constituted 6.4%. Overall range of age was 30-58 years and the mean age 
of presentation was 41.85years.3 patients presented like SNG, 3 patients 
presented like MNG and 1 patient presented with diffuse goiter. 
   The age range of SNG with malignancy was 30-34years. The mean age 
for SNG presenting malignancy was 31.3years. It was significantly lower 
than overall mean age for presentation of malignancy and was also lower 
than the mean of  benign clinical presentation of SNG.  
 The age range of MNG with malignancy was 40-58 years with the mean 
age of presentation 48 years. It was significantly higher than overall mean 
age for presentation of malignancy and higher than mean age for 
presentation of MNG 
   Of the seven cases two were microscopic papillary carcinoma, one was 
papillary carcinoma, three were follicular carcinoma and one lymphoma. 
Of  the 3 follicular carcinomas, one was widely invasive follicular 
carcinoma, one was minimally invasive follicular carcinoma and one was 
low grade follicular carcinoma. This observation was consistant  with the 
study of Hee-Nee Pang et al
[10]
 in reporting papillary carcinomas, 
follicular carcinomas and lymphoma  be detected in nodular goiters. 
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   In this study the incidence of papillary microcarcinoma in MNG was 
around 4.2% , consistent with the study of Hee-Nee Pang et al
[10]
,
 
that 
showed 4.9% of incidence. Incidence of papillary microcarcinoma in 
overall benign diseases was around 1.8%. According to Harach et al
[12 ]
  
papillary microcarcinoma was found in around 35% autopsy studies. In 
various surgical studies, incidence of papillary microcarcinoma in 
thyroidectomies showing incidence ranging from 2-25% (McConahey et 
al
[13]
 and  Fink A et al
[14]
)
 
. GH Sakorafas et al
[11]
 showed incidence of 
papillary micro carcinoma 7.1% in presumably benign thyroid diseases. 
CarliniM  et all
[15]
 showed 21.6% incidence MPC in benign thyroid 
diseases. Jean-Michel Prades et al
[29]
., and Roberta Gelmini et al
[30]
., 
showed incidence of 12.2% and 11.1% respectively. 
  Incidence of malignancy diagnosed in MNG was 6.25%. Of three cases 
two were papillary carcinoma and one was follicular carcinoma. Waseem 
Memon 
[16] 
et al study shows incidental malignancy in MNG is 7.6%. 
There was no details regarding papillary micro carcinoma in that study.   
  A study conducted by Pedamallu et al
[17] 
 showed incidence of 
malignancy in MNG was 10.2%, majority of cases(9 out of 10) being 
papillary carcinoma. A study from Hanumanthappa
[18]
 et al also showed 
similar findings. 
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  Review of the literature in all the above mentioned studies showed the 
predominant incidental malignancy occurring in MNG is papillary 
carcinoma. This study was also consistent with that.   
  Elio Roti et al
[19] 
meta analysis study showed age range for microscopic 
papillary carcinoma(MPC)  was 41.9 to 55 years. In the present study age 
of the two patients were 46 and 58 years. It also showed female to male 
ratio in MPC was 4.9:1. In the present study we had only 2 cases and they 
both were females.
 
 
  A study conducted by Ranil Fernando et al
[20] 
showed incidental 
malignancy in 8.8% of patients with benign thyroid diseases with 
papillary and follicular carcinomas occurring in equal frequency . This 
study  also showed papillary and follicular carcinoma having  equal 
incidence of occurrence in overall benign thyroid diseases. 
  There were 2 cases of follicular carcinoma diagnosed in 25 cases of 
FN&FN/NG. The incidence was 8%. Whereas Carrie C. Lubitz et al
[21]
 
showed the incidence as 11%. A study from Micheal Tuttle et al
[22] 
showed incidence of  malignancy in follicular neoplasm was 21%. Zubair 
W Baloch et al
[23] 
demonstrated the incidence as 31%.  
  Incidence of malignancy in Hashimoto‟s thyroiditis(HT) was 50% in 
this study. Four cases of  Hashimoto‟s thyroiditis were operated for 
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pressure symptoms. There was 1 case of papillary microcarcinoma 
existing in the background of HT and 1 case of low grade lymphoma 
presented with acute respiratory compromise. Study from Elias E. 
Mazokopakis et al
[24]
 showed coexistence of HT and Papillary carcinoma 
was present in 8.6% of thyroidectomy specimens. Incidence of papillary 
carcinoma in HT in this study was 25%. A study performed by Daniel 
Replinger et al
[25]
 showed detection of Papillary carcinoma in 29% of 
patients operated for HT. This was consistent with the incidence of 
papillary carcinoma in HT in this series. 
  Although primary lymphoma in thyroid is rare, there are several case 
reports of lymphoma arising from the pre existing HT in the thyroid that 
presented as acute airway compromise, Arullendran et al
[28] 
 , C D 
Thomas et al 
[27]
 etc. Scholefield JH et al
[26] 
 showed 23% of lymphomas 
had pre existing HT. The high incidence of lymphoma in this series might 
be due to low volume of cases operated for Hashimoto‟s thyroiditis.         
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SUMMARY 
1.      Benign thyroid diseases most commonly affected females, 
F:M=6.3:1. The most common clinical presentation was SNG in 
this study, although the most common final HPE diagnosis was 
MNG. Patients with SNG presented earlier age group than MNG. 
2. Incidence of malignancy in this study was 6.4%. Patients with 
MNG had slightly higher incidence of harbouring malignancy than 
SNG. Male patients had significantly higher incidence (>2 fold) 
than females.  
3.       According to this study, when considering age as a predictive 
factor incidence of malignancy could not be underestimated in 
young adult patients with SNG(mean age31.3years). Whereas 
incidence of malignancy in patients with MNG had older age group 
of distribution(mean age 48 years). 
4. Papillary micro carcinoma was the most commonly identified 
malignancy in patients with MNG and Follicular carcinoma in 
patients with SNG. 
5. Incidence of follicular carcinoma in patients with follicular 
neoplasm was 8%.  
  
89 
 
                                CONCLUSION 
 
       The  studies of Micheal Prades et al
[29]
., Carlini et al
[15]
., Roberta 
Gelmini et al
[30]
., showed an incidence of malignancy in benign thyroid 
diseases was above 10% and they were suggesting that Total 
thyroidectomy for all benign thyroid diseases in order to avoid second 
surgery. But the incidence in our study was only 6.4%. Considering the 
morbidity associated with the total thyroidectomy in all patients, it can be 
concluded that subjecting the specimens of  conservative thyroid 
surgeries, for serial sectioning technique in Histopathological 
examination will be sufficient, so that the positive cases can be identified 
and treated suitably. 
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                                        ANNEXURE I 
A STUDY ON INCIDENCE OF MALIGNANCY IN PATIENTS 
UNDERGOING SURGERY FOR BENIGN THYROID DISEASES 
 
Name  :    Age/Sex  :   I.P. No.  : 
Address  :     Occupation  :   
CHIEF COMPLAINTS  : 1.  
      2. 
Detailed History  : 
 H/O Swelling in the neck 
Duration :   Location:   Size: 
Onset :   Progression:    
 H/O Pain over the swelling : Y/N  
 H/O heat/cold intolerance : 
 H/O weight gain/weight loss : 
 H/O palpitatations, tremors, excessive sweating : 
 H/O loss of hair : 
 H/O constipation : 
 H/O menstrual abnormalities : 
 H/O dysphagia/dyspnoea/dysphonia : 
 H/O falling of eyebrows : 
Past History  : 
 H/O any chronic illness/ chronic drug intake/ surgeries : 
 H/O any irradiation in the past : 
Personal History  : 
 Diet habit : 
 H/O Smoking and alcohol intake :  
 Marital History : 
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Family History  :  
 H/O any similar illness among family members : 
 
GENERAL EXAMINATION  : 
 
 
LOCAL EXAMINATION OF NECK  : 
 Description of the swelling : 
 
 Tracheal position : 
 
 Carotid pulsation : 
 
 Examination of neck nodes : 
 
EYE SIGNS  : 
 
Pretibial myxodema : Y/N   Tremors : Y/N   
Tongue fibrillation : Y/N    Bruit : Y/N 
 
E.N.T. Examination : 
 
C.V.S : 
R.S : 
ABDOMEN : 
C.N.S : 
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INVESTIGATIONS  
1. Blood – Hb%:  TC:  DC:  ESR: 
 Platelets: 
2. Blood Urea :  Blood Sugar :  Serum 
Creatinine:  
3. Urine – Alb :  Sugar :  Deposits : 
4. Chest X-ray  
5. E.C.G 
6. Thyroid Function Tests 
7. U.S.G. Neck 
8. F.N.A.C 
9. CT/MRI 
 
DIAGNOSIS  : 
 
MANAGEMENT  : 
 MEDICAL : 
 
 SURGICAL : 
 
INTRA OPERATIVE FINDINGS : 
 
FINAL H.P.E. REPORT : 
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                              ANNEXURE II 
ABBREVIATIONS: 
 AGES – Age, Grade of the tumor, Extent, Size 
AMES – Age, metastases, extrathyroidal extension, size 
CG       -  Colloid goiter 
CT       -  Computarised tomography 
DIT      -  Di-iodotyrosine 
MIT     -  Mono-iodotyrosine 
FNAC  - Fine needle aspiration cytology 
FDG    - Fluoro deoxy glucose 
FN        - Follicular neoplasm 
FT3      - Free tri-iodothyronine 
FT4      - Free thyroxine 
HPE     - Histopathological examination 
MACIS – metastases, age, completeness of surgery, invasion, size 
MEN   - Multiple endocrine neoplasia  
MIT      - Mono-iodotyrosine 
MNG   - Multinodular goiter 
MPC   - Papillary micro carcinoma 
MTC   - Medullary thyroid carcinoma 
NG      - Nodular goiter 
PET    - Positran emission tomography 
RAI    - Radio active iodine 
Tg       - Thyroglobulin 
TSH    - Thyroid stimulating hormone 
USG   - Ultrasonogram 
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S.NO NAME AGE SEX IP. NO CLINICAL USG TFT FNAC PROCEDURE HPE REPORT 
1 Madhammal 32 Female 42877 MNG-Non toxic MNG Euthyroid FN/ NG Near total thyroidectomy Adenomatous goitre 
2 vijayalakshmi 40 Female 41477 SNG-Lt lobe SNG  Euthyroid FN Lt hemithyroidectomy Follicular adenoma 
3 Palanathal 60 Female 44661 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
4 saritha 21 Female 46659 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy Hashimoto's thyroiditis 
5 saroja 30 Female 47359 SNG-Rt lobe SNG  Euthyroid FN Rt hemithyroidectomy Follicular adenoma 
6 vasanthi 42 Female 38486 SNG-Rt lobe SNG Euthyroid Colloid goitre Rt hemithyroidectomy MNG 
7 kaveri 40 Female 48486 Diffuse goitre Diffuse goitre Hyperthyroid MNG-TOXIC Subtotal thyroidectomy Toxic goitre 
8 Arukkani 40 Female 46255 SNG-Rt lobe SNG Euthyroid FN Lt hemithyroidectomy Follicular adenoma 
9 Kaliyammal 57 Female 48058 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy Hurthlecell adenoma 
10 Anbarasi 45 Female 50108 MNG-Non toxic MNG Euthyroid Hashimoto's thyroiditis Subtotal thyroidectomy Hashimoto's thyroiditis 
11 Rajarathinam 55 Male 56743 Diffuse goitre Diffuse goitre Euthyroid Hashimoto's thyroiditis Isthumectomy Low grade lymphoma 
12 Deivanai 30 Female 50106 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
13 Vanitha 56 Female 50038 SNG-Rt lobe SNG Euthyroid FN/ NG Rt hemithyroidectomy MNG 
14 Ravikumar 25 Male 49680 MNG-Non toxic MNG Euthyroid NG Near total thyroidectomy Adenomatous goitre 
15 Mariyagnanam 47 Female 51556 MNG-Non toxic MNG Euthyroid Adenomatous goitre Subtotal thyroidectomy Adenomatous goitre 
16 Dhanalakshmi 29 Female 50999 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
17 Rajalakshmi 60 Female 52559 MNG-Non toxic MNG Euthyroid MNG Subtotal thyroidectomy MNG 
18 Mani 65 Male 52372 SNG-Rt lobe SNG Hyperthyroid Colloid goitre Rt hemithyroidectomy MNG 
19 Mala 40 Female 57442 MNG-Non toxic MNG Euthyroid FN/NG Rt hemithyroidectomy Follicular adenoma 
20 Subbulakshmi 57 Female 59652 MNG-Non toxic MNG Euthyroid MNG Subtotal thyroidectomy MNG 
21 Suryaprakash 17 Male 59094 SNG-Rt lobe SNG Euthyroid FN Rt hemithyroidectomy Tuberculous lesion 
22 Nagarajan 35 Male 53367 Diffuse goitre MNG Hyperthyroid MNG-TOXIC Subtotal thyroidectomy MNG-TOXIC 
23 Sameera  27 Female 59922 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
24 Munirabanu  26 Female 57474 SNG-Lt lobe SNG Euthyroid FN Lt hemithyroidectomy Follicular adenoma 
25 Sudharani 25 Female 61303 SNG-Lt lobe SNG Euthyroid FN/NG Lt hemithyroidectomy Follicular adenoma 
26 Savithri 40 Female 62094 SNG-Rt lobe SNG Euthyroid FN/NG Rt hemithyroidectomy Adenomatous goitre 
27 Krishnaveni 50 Female 62088 MNG-Non toxic MNG Euthyroid FN Subtotal thyroidectomy MNG 
28 Lakshmi 30 Female 63631 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Adenomatous goitre 
29 Dhanabhakiyam 36 Female 63627 SNG-Rt lobe SNG Euthyroid FN Rt hemithyroidectomy Follicular adenoma 
30 Chandra 45 Female 63451 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy Adenomatous goitre 
31 Girija 42 Female 67258 MNG-Non toxic MNG Euthyroid FN Near total thyroidectomy MNG 
32 Gnanasundari 28 Female 67867 SNG-Rt lobe SNG Euthyroid Colloid goitre Rt hemithyroidectomy Follicular adenoma 
33 Selvi 30 Female 70176 SNG-Rt lobe SNG Euthyroid FN/NG Rt hemithyroidectomy Follicular adenoma 
34 Anandalakshmi 32 Female 72609 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Follicular adenoma 
35 Ambika 29 Female 814 SNG-Rt lobe SNG Euthyroid NG Lt hemithyroidectomy Adenomatous goitre 
36 Saraswathy 65 Female 2639 Diffuse goitre Diffuse goitre Hyperthyroid MNG-TOXIC Subtotal thyroidectomy Toxic goitre 
37 Devi 36 Female 4256 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Adenomatous goitre 
38 Vimala 36 Female 8086 MNG-Non toxic MNG Euthyroid MNG Subtotal thyroidectomy MNG 
39 Sainaba 50 Female 7160 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Follicular adenoma 
40 Subbammal 65 Female 8420 Diffuse goitre Diffuse goitre Euthyroid Colloid goitre Subtotal thyroidectomy MNG 
41 Selvi 23 Female 7468 SNG-Rt lobe SNG Euthyroid FN Subtotal thyroidectomy Follicular adenoma 
42 Rahim 88 Male 7624 SNG-Lt lobe MNG Euthyroid Colloid goitre Lt hemithyroidectomy MNG 
43 Neelambal 27 Female 12037 MNG-Non toxic MNG Euthyroid Colloid goitre Subtotal thyroidectomy MNG 
44 Margret rani 55 Female 18380 Diffuse goitre MNG Hyperthyroid MNG-TOXIC Near total thyroidectomy Adenomatous goitre 
45 Jaya sakthivel 55 Male 9530 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy Follicular adenoma 
46 Vijayalakshmi 40 Female 14594 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Follicular adenoma 
47 Jemisha 33 Male 15532 Diffuse goitre MNG Hyperthyroid FN/NG Near total thyroidectomy MNG 
48 Maheswaran 25 Male 16589 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy Adenomatous goitre 
49 Maragadham 25 Female 16593 MNG-Non toxic MNG Euthyroid Adenomatous goitre Subtotal thyroidectomy Adenomatous goitre 
50 Pappammal 45 Female 17877 MNG-Non toxic MNG Euthyroid MNG Near total thyroidectomy MNG 
51 Krishnan 58 Male 15650 Diffuse goitre Diffuse goitre Euthyroid Colloid goitre Subtotal thyroidectomy Colloid goitre 
52 Chitra 39 Female 20967 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy Follicular adenoma 
53 Jansy 26 Female 23058 Isthmus nodule Isthmus nodule Euthyroid NG Isthumectomy Adenomatous goitre 
54 Arukkani 34 Female 21516 MNG-Non toxic MNG Euthyroid Hashimoto's thyroiditis Subtotal thyroidectomy Hashimoto's thyroiditis 
55 Radha 25 Female 46578 SNG-Lt lobe SNG Euthyroid FN Lt hemithyroidectomy Adenomatous goitre 
56 Sulochana 36 Female 23024 SNG-Rt lobe SNG Euthyroid FN/NG Rt hemithyroidectomy Follicular adenoma 
57 Shameen 25 Female 22080 MNG-Non toxic MNG Euthyroid FN/NG Subtotal thyroidectomy Follicular adenoma 
58 Elizabeth 45 Female 32008 SNG-Rt lobe SNG Euthyroid Adenomatous goitre Rt hemithyroidectomy Follicular adenoma 
59 Ponnammal 55 Female 20784 MNG-Non toxic MNG Euthyroid Adenomatous goitre Subtotal thyroidectomy Adenomatous goitre 
60 Fathima 28 Female 24141 SNG-Rt lobe MNG Euthyroid NG Rt hemithyroidectomy Follicular adenoma 
61 Padma 38 Female 21744 SNG-Rt lobe SNG Euthyroid FN Lt hemithyroidectomy MNG 
62 Thenmozhi 37 Female 21971 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
63 Radhika 32 Female 24970 SNG-Rt lobe SNG Euthyroid FN Rt hemithyroidectomy Follicular adenoma 
64 Kaliyammal 35 Female 26372 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
65 Kousalya 42 Female 27063 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy MNG 
66 Jothimani 55 Female 24812 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
67 Sumathi 25 Female 27518 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
68 Bhuvaneshwari 45 Female 28305 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy MNG 
69 Selvamani 46 Female 26883 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy Follicular adenoma 
70 Jeyasri 46 Female 28503 MNG-Non toxic MNG Euthyroid Hashimoto's thyroiditis Near total thyroidectomy Microscopic -PAP 
Ca/Hashimotos 
71 Mariammal 36 Female 27276 MNG-Non toxic MNG Euthyroid NG Near total thyroidectomy Hashimoto's thyroiditis 
72 Chandrakala 35 Female 34327 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy MNG 
73 Neelavathy 58 Female 35863 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MIcroscopic -PAP Ca/MNG 
74 Natchammal 49 Female 36120 SNG-Rt lobe MNG-Rt lobe Euthyroid NG Rt hemithyroidectomy Adenomatous goitre 
75 Rajesh 36 Male 37737 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Adenomatous goitre 
76 Shanthi 28 Female 37306 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy Adenomatous goitre 
77 Nandhini 20 Female 38351 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Adenomatous goitre 
78 Radhika 27 Female 38347 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Follicular adenoma 
79 Mahalakshmi 32 Female 38542 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
80 Rayathal 32 Female 37769 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy Adenomatous goitre 
81 Ponnammal 30 Female 38613 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Follicular carcinoma 
82 Thangamani 70 Female 32206 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
83 Revathy 27 Female 40752 SNG-Lt lobe SNG Euthyroid FN Lt hemithyroidectomy Follicular adenoma 
84 Valliyammal 50 Female 36616 MNG-Non toxic MNG Euthyroid Adenomatous goitre Subtotal thyroidectomy Adenomatous goitre 
85 Dhanabhakiyam 40 Female 41474 MNG-Non toxic MNG Euthyroid NG Near total thyroidectomy MNG 
86 Jannath 45 Female 41657 MNG-Non toxic MNG Euthyroid MNG Subtotal thyroidectomy MNG 
87 Shanmugasundaram 34 Male 48329 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Papillary carcinoma 
88 Santhanam 53 Male 43076 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
89 Abhijeet Viswas 36 Male 44698 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Follicular adenoma 
90 Ramathal 38 Female 44652 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Adenomatous goitre 
91 Pushpalatha 30 Female 45348 SNG-Rt lobe SNG Euthyroid FN/NG Rt hemithyroidectomy Follicular carcinoma 
92 Vijaya 36 Female 46586 SNG-Lt lobe SNG Euthyroid FN/NG Lt hemithyroidectomy Follicular adenoma 
93 Rukmani 55 Female 47918 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy MNG 
94 Sathyapriya 16 Female 48148 Isthmus nodule Isthmus nodule Euthyroid NG Isthumectomy Follicular adenoma 
95 Chikmuthu 38 Male 51155 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy Follicular adenoma 
96 Arukkani 30 Female 60169 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy Follicular adenoma 
97 Selvi 43 Female 52949 SNG-Lt lobe SNG Euthyroid Colloid goitre Lt hemithyroidectomy Follicular adenoma 
98 Rani 29 Female 53325 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Follicular adenoma 
99 Umadevi 23 Female 57985 SNG-Lt lobe SNG Euthyroid NG Lt hemithyroidectomy Adenomatous goitre 
100 Sudha 22 Female 58184 SNG-Rt lobe SNG Euthyroid NG Rt hemithyroidectomy Follicular adenoma 
101 Kanaga 26 Female 58816 MNG-Non toxic MNG-Rt lobe Euthyroid NG Rt hemithyroidectomy Adenomatous goitre 
102 Pavithra 17 Female 54309 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
103 Thangamani 25 Female 61601 SNG-Rt lobe SNG Euthyroid Colloid goitre Rt hemithyroidectomy Adenomatous goitre 
104 Sangeetha 29 Female 62490 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
105 Pappathi 40 Female 63882 MNG-Non toxic MNG Euthyroid FN/NG Near total thyroidectomy Follicular carcinoma 
106 Amalamary 62 Female 65155 MNG-Non toxic MNG Euthyroid Adenomatous goitre Rt hemithyroidectomy Adenomatous goitre 
107 Dhanalakshmi 34 Female 65759 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy MNG 
108 velumani 21 Female 38765 MNG-Non toxic MNG Euthyroid NG Subtotal thyroidectomy Adenomatous goitre 
109 Lakshmi 35 Female 53170 MNG-Non toxic MNG Euthyroid MNG Subtotal thyroidectomy Adenomatous goitre 
 
